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  ABSTRACT 
I 
 
ABSTRACT 
The p53 protein is one of the most well-known tumor suppressor proteins, and it plays 
a variety of functions in somatic cells. Once activated, p53 induces cell cycle arrest 
and inhibits cell proliferation. Since it was found that p53 is highly expressed in 
murine embryonic stem cells, a cell type that proliferates very fast because of a 
shortened G1 phase, it remained a mystery whether p53 is active in this cell type.  
I observed that a significant part of p53 is localized in the nucleus of murine 
embryonic stem cells and that the majority of this nuclear p53 is bound to DNA. In 
addition, the anti-proliferative activity of p53 is compromised in stem cells, and this 
control is due, at least in part, to the high amount of MDMX that is present in 
embryonic stem cells. This high amount of MDMX is most likely due to exclusion of 
exon 7 of the MDMX RNA during retinoic acid induced differentiation. MDMX 
co-eluted with p53 from sucrose gradient assays and downregulation of MDMX in 
mESCs increased MDM2 abundance, a transcriptional target of p53, indicating that 
MDMX controls p53’s transcriptional activity in stem cells. P53 is posttranslationally 
modified in mESCs and these modifications endow a neutral isoelectric point (pI) of a 
fraction of the p53 protein that is only present in stem cells. Moreover, according to 
its nuclear localization in mESCs, p53 influences the transcriptome of mESCs. 
However, in contrast to the anti-proliferative activity that p53 has in differentiated 
cells, p53 controls transcription of pro-proliferative genes in embryonic stem cells 
including c-myc and c-jun. Chromatin-Immunoprecipitation showed that p53 binds to 
the responsive element of these proto-oncogenes. The impeded anti-proliferative 
activity of p53 and the induction of certain proto-oncogenes by p53 in murine 
embryonic stem cells can explain why stem cells proliferate efficiently despite having 
high levels of p53.  
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  ZUSAMMENFASSUNG 
III 
 
ZUSAMMENFASSUNG 
Das p53-Protein ist eines der bekanntesten Tumorsuppressorproteine, und es hat eine 
Vielzahl von Funktionen in somatischen Zellen. Einmal aktiviert, induziert p53 
Zellzyklusarrest und Apoptose. In murinen embryonalen Stammzellen (mESCs), 
einem Zelltyp, der aufgrund einer verkürzten G1 Phase sehr schnell proliferiert, ist 
p53 sehr stark exprimiert. Es war deshalb bisher unklar, ob p53 in diesen Zelltyp aktiv 
ist.  
Ich beobachtete, dass ein wesentlicher Teil des p53 Proteins im Kern von 
embryonalen Stammzellen der Maus lokalisiert ist Jedoch ist die anti-proliferative 
Aktivität von p53 in Stammzellen beeinträchtigt. Dies ist, zumindest teilweise, auf die 
große Menge an MDMX zurück zu führen, die in embryonalen Stammzellen 
vorhanden ist. Diese große Menge an MDMX geht wahrscheinlich auf den Ausschluss 
von Exon 7 der MDMX RNA während der Differenzierung zurück. Die 
Herunterregulierung der MDMX mRNA in mESCs erhöhte die Proteinmenge von 
MDM2, einem Zielgen von p53. Damit ist es wahrscheinlich, dass MDMX die 
Transkriptionsaktivität von p53 kontrolliert. Außerdem ist das p53 Protein in mESCs 
posttranslationell modifiziert. Diese posttranslationellen Modifikationen sorgen für 
einen neutralen isoelektrischen Punkt (pI) einer Fraktion der p53-Proteine. Im 
Einklang mit der nuklearen Lokalisation von p53 beobachtete ich, dass p53 das 
Transkriptom von mESCs beeinflusst. Allerdings beobachtete ich, dass p53 anstelle 
der anti-proliferativen Aktivität die es in differenzierten Zellen hat, in mESCs die 
Transkription von pro-proliferative Genen einschließlich c-myc und c-Jun steuert. 
Chromatin-Immunopräzipitationen zeigten, dass p53 an den Promoter dieser 
Proto-Onkogene bindet und sich damit wie mutiertes p53 verhält. Die behinderte 
antiproliferative Aktivität von p53 und die Induktion bestimmter Proto-Onkogene 
durch p53 in murinen embryonale Stammzellen können erklären, warum sich 
Stammzellen trotz des hohen p53 Spiegels effektiv vermehren können. 
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1 INTRODUCTION 
Embryonic stem cells are cells that have the capability of differentiating into all kinds 
of cells. They are particularly present at the beginning of life. Thus any mutation that 
arises in embryonic stem cells endows a more serious problem since this mutation is 
carried over into the whole developing organism which is not the case if such a 
mutation happens in somatic cells. p53, a tumor suppressor protein well-known as 
“guardian of the genome”, plays a critical function in cells, including the maintenance 
of genomic integrity after genotoxic damage. In embryonic stem cells, p53 is highly 
abundant but its regulation and function is incompletely understood.  
 
1.1 Embryonic stem cells. 
Embryonic stem cells (ESCs) are a special type of cells that can be found in all 
multi-cellular organisms. They can divide and produce more stem cells, a process that 
is called self-renewal and they can differentiate into diverse specialized cell types. In 
mammals, two types of stem cells exist, namely embryonic stem cells, which are 
isolated from the inner cell mass of blastocysts, an early-stage of development and 
adult stem cells that are found throughout the body after embryonic development. 
Since adult stem cells are found in matured tissues, they are also called tissue stem 
cells (Loeffler and Roeder, 2002). Adult stem cells are usually required to replenish 
dying cells and to regenerate damaged tissues. According to their function, adult stem 
cells are subdivided into hematopoietic stem cells (Spangrude et al., 1988), mammary 
stem cells (Liu et al., 2005), intestinal stem cells (van der Flier and Clevers, 2009), 
mesenchymal stem cells (Phinney and Prockop, 2007), endothelial stem cells 
(Ferguson et al., 2005), neural stem cells (Stemple and Mahanthappa, 1997) and 
olfactory stem cells (Murrell et al., 2005).  
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Principally, the self-renewal capacity and pluripotency are the two main 
characteristics of stem cells. Self-renewal means that by cell division the stem cells 
create daughter cells that also have the self-renewal and pluripotency capacity. While 
ESCs have unlimited self-renewal potential , this is not the case for adult stem cells, 
which have a more limited self-renewal potential (Thomson et al., 1998; Roobrouck et 
al., 2008) 
Another characteristic of stem cells is their ability to differentiate. While embryonic 
stem cells differentiate into all derivatives of the three primary germ layers: ectoderm, 
mesoderm, and endoderm, and into each of the more than 220 cell types in the adult 
body ( Martin, 1981) possess adult stem cells a limited developmental potential and 
can only differentiate into cell types of specific lineages (Ulloa-Montoya et al., 2007).  
The self-renewal capacity of ESCs is accompanied by rapid proliferation because of a 
shortened G1 phase (Neganova and Lako, 2008). High levels of CDK2-cyclin 
A/cyclin E in ESCs allow fast entry of stem cells into S phase. When ESCs start 
differentiation the G1 phase is extended and cell proliferation is slowed down 
(Neganova and Lako, 2009).  
Research on ESCs became very popular in recent years because of their potential to 
be used for regenerative medicine. Fifteen years ago, the successful isolation of 
human ESCs promised to enable the repair of tissue that has been damaged through 
disease or injury (Donovan and Gearhart, 2001; Thomson and Odorico, 2000; Wobus, 
2001). Since that time, scientists predict that directed differentiation of ESCs may 
facilitate the clinical application of cell transplantation therapy. In January 2009, the 
US Food and Drug Administration (FDA) approved the first clinical trial for using 
human ESCs to treat patients with spinal cord injury (Yamanaka, 2009). However, 
ethical concerns and immunological rejection after allogenic cell transplantation are 
still main obstacles for the use of ESCs in clinical applications (McLaren, 2001). One 
way to circumvent these problems is to induce a pluripotent status in somatic cells by 
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direct reprogramming. By transfection of a combination of transcription factors, cells 
with stem cell like properties can be made from basically every differentiated cell 
(Okita et al., 2007; Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Wernig et 
al., 2007; Yu et al., 2007). These cells are called induced pluripotent stem cells 
(iPSCs), the third type of stem cells. The iPSCs technology can thus overcome two 
vital barriers associated with human ESCs: immunological rejection after 
transplantation and ethical concerns regarding the use of human embryos. 
Patient-derived iPSCs can generate a variety of somatic cells with the same genetic 
information as the patient (Jang et al., 2012). These cells can be used to construct 
disease models and to screen for effective and safe drugs, as well as to treat patients 
by cell transplantation therapy. Unfortunately, the low frequency of reprogramming 
and the tendency to induce malignant transformation currently compromises the 
clinical utility of this powerful approach (Okita et al., 2007).  
 
1.2 The tumor suppressor protein p53. 
The p53 protein is one of the most well-investigated tumor suppressor proteins. p53 
was firstly discovered in 1979 (Kress et al., 1979; Lane and Crawford, 1979; Linzer 
and Levine, 1979). Immediately after its discovery, it was assumed that p53 is a 
transformation-related protein, which accumulates in the nuclear part of tumor cells 
and tightly binds to the simian virus 40 (SV40) large T antigen (Lane and Crawford, 
1979; Linzer and Levine, 1979). Because of the observed oncogenic activities and its 
high expression in murine and human tumor cells, p53 was originally defined as an 
oncogene (Dippold et al., 1981). However, about ten years after its initial discovery it 
became clear that the oncogenic p53 that was found in human tumors was actually 
mutant (Baker et al., 1989; Finlay et al., 1989). Subsequent studies proved that p53 is 
a tumor suppressor protein that is mutated in over 50% of human carcinomas and to 
almost 100% in families with the cancer-prone Li-Fraumeni syndrome 
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(Santibanez-Koref et al., 1991; Sedlacek et al., 1998). As a so-called “cellular gate 
keeper” and “guardian of the genome”, p53 plays a fundamental role in coordinating 
the cellular response to a wide range of cellular stresses (Lane, 1992; Levine, 1997).  
 
1.3 The domain structure of p53 
The p53 protein is composed of 393 amino acids and can be divided into several 
functional domains including a transactivation domain, a proline-rich domain, a DNA 
binding domain, a nuclear localization signal, a tetramerization domain, a nuclear 
export signal and a C-terminal regulatory domain (Boehme and Blattner, 2009). All 
these domains can be extensively modified with post-translational modifications 
which modulate p53’s stability and activity (Boehme and Blattner, 2009). In addition, 
multiple proteins associate with p53. Proteins that interact with the N-terminal 
transactivation domain of p53 protein are e.g. mouse double minute 2 homolog 
(MDM2) and mouse double minute 4 homolog (MDMX, also known as MDM4), two 
negative regulators of p53, p300, an essential histone acetyltransferase, the TATA 
binding protein (TBP) and the TBP associated factor 9 (TAF9, also known as TAFII31; 
Chen et al., 1993; Danovi et al., 2004; Finlan and Hupp, 2004; Shi et al., 2009; Jabbur 
et al., 2002). In proximity to the transactivation domain, (residues 63-97) is the 
proline-rich-domain, that includes five copies of PXXP, where P represents proline 
and X any amino acid. This domain is involved in the induction of p53-dependent 
apoptosis (Sakamuro et al., 1997; Venot et al., 1998; Walker and Levine, 1996; Zhu et 
al., 1999). and also regulates the stability of the p53 protein (Sakamuro et al., 1997). 
The DNA binding domain is the main component of the central core of the p53 
protein. This domain is required for sequence-specific DNA binding. This domain is 
furthermore frequently mutated. In fact, over 80% of mutations of the p53 gene are 
found between the residues 126 and 306 (Cho et al., 1994). The nuclear localization 
signal (NLS) contains a core of basic amino acids that is surrounded by amino acids 
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that break the α-helical structure (Kalderon et al., 1984). The NLS is required for the 
binding to importin-α and allows the translocation of p53 into the nucleus (Gorlich 
and Mattaj, 1996; Koepp and Silver, 1996; Shaulsky et al., 1990). In proximity to the 
NLS is the tetramerization domain (TET). This domain is indispensable for p53 
binding to DNA and p53’s transcriptional activity which can be explained by the fact 
that p53 monomers bind to DNA in a cooperative manner (Balagurumoorthy et al., 
1995). Therefore, the affinity of the p53 protein for its response element is 
dramatically decreased when the tetramerization domain has been deleted 
(Balagurumoorthy et al., 1995). Only when p53 is able to form homooligomers, it is 
able to be fully act as a transcription factor and to activate or suppress distinct target 
genes that contain p53 sequence-specific binding sites (Davison et al., 1998). The 
nuclear export signal (NES) is essential for p53 exportation out of the nucleus and its 
cytoplasmic degradation (Freedman and Levine, 1998). Interestingly, when p53 
proteins form tetramers, e.g. in response to DNA damage, the NES signal is blocked 
(Stommel et al., 1999). The last domain of p53 is the regulatory domain (REG), a 
domain that has raised the most controversial discussion about its function among the 
different domains of p53. The first model claims that REG has an allosteric influence 
on the DBD of the p53 protein (Halazonetis and Kandil, 1993; Hupp and Lane, 1994; 
Sakaguchi et al., 1997). The second model claims that REG sterically hinders the 
binding of p53 to unspecific DNA sequences (Anderson et al., 1997). The C-terminal 
domain of p53 is, extensively posttranslationally modified and these modifications 
have a regulatory effect on p53 activity (Appella and Anderson, 2000).  
 
Figure 1.1 | Schematic structure of the p53 protein. p53 consists of an N-terminal part, a central 
core and a C-terminal part. The N-terminal part contains the transactivation domain (TAD), that 
associates with distinct transcriptional activators and that is required for transactivation activity, 
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and the proline rich domain (PRD). The DNA binding domain (DBD) builds the core of the p53 
protein. The C-terminal tail contains the nuclear localization signal (NLS), the tetramerization 
domain (TET), the nuclear export signal (NES) and the regulatory domain (REG). Numbers 
indicate the starting and the terminal amino acid of each domain.  
 
1.4 Cellular functions of p53. 
As a tumor suppressor protein, p53 primarily prevents inappropriate cell proliferation 
and maintains genome integrity following genotoxic stress (Vogelstein et al., 2000; 
Vousden and Lu, 2002). Basically, p53 functions in two ways: one is that p53 is a 
transcription factor that associates with specific DNA sequences and transactivates a 
number of target genes whose protein products induce cell cycle arrest, apoptosis and 
senescence (Riley et al., 2008). In addition to this nuclear activity, p53 also possesses 
biological activities in the cytoplasm that are transcription-independent. This cytosolic 
activity of p53 has been identified about a decade of years ago when scientists 
overexpressed a p53 mutant that lacked most of the DNA-binding domain and that 
was completely deficient in transactivation function (Haupt et al., 1995). Subsequent 
studies showed that overexpression of a variety of transactivation-incompetent p53 
mutants could indeed efficiently induce apoptosis in human cells (Kakudo et al., 
2005). Consistent with these observations, it was found that apoptosis induced by 
stabilization of an ectopically expressed temperature-sensitive mutant of p53 induced 
cell death in the absence of RNA and protein synthesis (Caelles et al., 1994). Similarly, 
p53 was found to trigger apoptosis even in the absence of a nucleus (Chipuk et al., 
2003).  
1.4.1 Transactivation-dependent function of p53. 
Based on the phenomena that p53 can provide a transcriptional activation function 
when fused to a DNA-binding protein GAL4 (Fields and Jang, 1990) and that p53 can 
bind to DNA (Lane and Gannon, 1983), and such binding was altered in each of 5 
human tumor-derived forms of mutant p53 tested (Kern et al., 1991a); p53 was 
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proposed to have a putative sequence-specific binding function (Kern et al., 1991a). 
Later, a human DNA sequence was identified to which wild type human p53 
specifically binds in vitro (Kern et al., 1991b). Several years ago, forty-eight 
binding-sites for p53 were observed along chromosome twenty and twenty-two in 
HCT116 cells that expresses wild type human p53 with high confidentiality (Cawley 
et al., 2004). By extrapolation, it was predicted that the whole genome may contain 
approximately 1,600 binding sites for p53 (Cawley et al., 2004). A few years after this 
estimation, Riley et al. screened for genes that are regulated by p53 and found one 
hundred and sixty response elements for p53 and one hundred and twenty-nine genes 
that are regulated by p53 (Riley et al., 2008). Of note, the p53 protein can both 
activate and repress gene transcription.  
1.4.1.1 Transactivation of target genes by p53. 
One of the most extensively studied functions of p53 protein is its ability to stimulate 
RNA polymerase II-dependent gene transcription. This activation of gene 
transcription by p53 can be explained by several properties of p53. Firstly, p53 is able 
to bind to DNA (Lane and Gannon, 1983). Secondly, p53 is able to recruit chromatin 
remodeling factors (Lee et al., 2002) and histone acetyltransferases and 
methyltransferases to promoters of target genes (An et al., 2004; Avantaggiati et al., 
1997; Barlev et al., 2001; Hsu et al., 2004; Lill et al., 1997). These enzymes alter the 
structure of chromatin by histone modification, and thus allow general transcription 
factors and the RNA polymerase access to the transcription start site that otherwise 
would be inaccessible. This model has been supported by showing a physical and 
functional association of p53 and p300, one of the histone acetyltransferases 
(Espinosa and Emerson, 2001; Gu and Roeder, 1997; Hsu et al., 2004). The third 
property is that p53 facilitates the formation of a preinitiation complex by directly 
binding to the components of the mediator complex (Figure 1.2; Gu et al., 1999). The 
p53 protein furthermore enhances the affinity of basal transcription factors like TFIIA 
and TFIID to the promoters of target genes by directly associating with them. This 
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alters the conformation of the transcription complexes and allows the initiation of 
transcription (Ko and Prives, 1996; Xing et al., 2001). Most interestingly, the 
chromatin around p53’s response elements is maintained in an open conformation 
which means that the chromatin is accessible to RNA polymerase both under-stressed 
and non-stressed conditions (Graunke et al., 1999; Braastad et al., 2003).  
 
Figure 1.2 | p53 activation and regulation of target gene expression. When cells have been 
exposed to different cellular stresses which have the potential to lead to cell transformation p53 
becomes activated. This is in part due to phosphorylation by several kinases at certain residues. 
Activated p53 then forms tetramers and binds to responsive elements of target genes. The binding 
of p53 tetramers to responsive elements recruits co-activators, like histone acetyltransferases 
(HAT) and TATA binding protein-associated factors (TAFs). The most essential pathways that are 
activated by p53 lead to cell-cycle arrest, senescence and apoptosis (Riley et al., 2008). RE, 
responsive element; P, phosphorylation; Ac, acetylation; Me, methylation. (Figure from Riley et 
al., 2008, with modifications)  
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The p53 protein is activated in response to a variety of cellular signals, including 
DNA damage, telomere shortening, hypoxia, thermic shock, mitotic spindle damage, 
unfolded proteins, improper ribosomal biogenesis, nutrition deprivation and even after 
overexpression of oncogenes (Levine et al., 2006; Vogelstein et al., 2000). In principle, 
there are three primary outcomes after p53 activation which is cell cycle arrest, 
apoptosis and senescence respectively. Cell cycle arrest is a transient halt of cell 
proliferation, which allows the DNA repair machinery to correct mistakes that have 
occurred during DNA replication or after genotoxic insults prior to the next cell 
division. Apoptosis leads finally to the killing of the cells whereas senescence 
interferes with the cells capacity to divide. The choices between these cell fates in a 
stressed cell depend on a number of variables, which indicates that the p53 pathway 
may also sense the activity of other signal transduction pathways. In line with this 
idea induce different cellular stresses distinct groups of p53 target genes 
(Murray-Zmijewski et al., 2008; Vousden and Prives, 2009). This differential 
activation of target genes may contribute to the decision about the final fate of the cell 
after p53 activation. 
1.4.1.2 Transrepression of target genes by p53. 
In addition to its well-studied role in transcriptional activation, p53 has also been 
shown to repress a wide range of target gene (Burns and El-Deiry, 2003; Mirza et al., 
2003; Robinson et al., 2003; Sax et al., 2003; Riley et al., 2008). Currently, four 
mechanisms are discussed that lead to transcriptional repression by p53. One 
possibility is that p53 binds directly to the response element of target genes and 
recruits co-factors that mediate the repression. One of the co-factors that have been 
shown to mediate transrepression is histone deacetylase 1 (HDAC1). HDAC1 is 
recruited to promoter regions of target gene via a p53-dependent interaction with 
mSIN3A (Murphy et al., 1999). The second possibility is that p53 activates 
transcription of a repressor protein which then inhibits transcription of some genes. 
For example, p53 regulates p21 expression, which is an inhibitor of cyclin-dependent 
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kinase (Riley et al., 2008). The induction of p21 inhibits the phosphorylation of the 
retinoblastoma protein (Niculescu et al., 1998; Xiong et al., 1993) and this inhibition 
of the phosphorylation of the retinoblastoma proteins keeps E2F-1 in check and thus 
prevents the transcription of E2F-1 regulated genes (Delavaine and La Thangue, 
1999). The third mechanism by which p53 may repress gene transcription is by 
binding competitively to the response elements and by this hindering transcriptional 
regulator to access the response elements. For instance, p53 binds to the promoter of 
the alphafeto protein (AFP), displaces the transcriptional activator and by this 
represses afp expression (Lee et al., 1999). The last possibility for transcriptional 
repression is by association with other proteins. By this, p53 can associate with the 
promoter region of some genes which have no p53 responsive element. The cyclin B2 
promoter, for instance, contains no p53 response element. However, it contains a 
NF-Y recognition site. Promoter-bond NF-Y can then interact with p53 and p53 can 
recruit HDAC1 leading to the repression of the cyclin B2 promoter (Imbriano et al., 
2005). 
1.4.2 Transactivation-independent functions of p53. 
In addition to its nuclear functions, p53 also possesses biological activities in the 
cytosol that are transcription-independent. For instance, p53 translocates to 
mitochondria in response to hypoxia (Sansome et al., 2001). Here, p53 triggers the 
assembly of pro-apoptotic factors of the Bcl2 family at the outer membrane of the 
mitochondria and the formation of multimeric structures resulting in mitochondrial 
outer membrane permeabilization (MOMP; Leu et al., 2004; Mihara et al., 2003; Moll 
et al., 2006). MOMP facilitates the release of cytochrome c, a pro-apoptotic protein 
that is retained in the compartment between the inner and outer membrane of 
mitochondria (Kroemer et al., 2007; Leu et al., 2004). Principally, apoptosis induced 
by cytoplasmic p53 does not require p53’s transcriptional activity. However, there is 
clearly a cross-talk or interdependence between the cytoplasmic and nuclear p53 since 
the sequestration of cytoplasmic p53 by the anti-apoptotic Bcl-XL protein is regulated 
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by Puma, which is a target gene of p53 and capable of releasing p53 from the 
anti-apoptotic Bcl2 proteins to activate Bax (Chipuk et al., 2005).  
 
1.5 The regulation of p53 stability and activity. 
As p53 is a tumor suppressor protein that inhibits cell proliferation, p53’s function has 
to be tightly controlled to permit normal cell proliferation. Therefore, under normal 
conditions, p53 abundance is kept at a low level and in an inactive and latent form 
(Levine, 1997). p53’s function can then be induced rapidly through inducing 
posttranslational modifications (PTMs) and stabilization of the p53 protein.  
1.5.1 The regulation of p53 stability. 
p53’s stability is primarily regulated by different ubiquitin-ligases. The most 
well-studied ubiquitin ligase for p53 is MDM2 which induces both 
monoubiquitination and polyubiquitination of p53. Polyubiquitinated p53 is then 
recognized by 26S proteasomes where it is degraded while monoubiquitinated p53 is 
exported into the cytoplasm (Li et al., 2003; Honda et al., 1997). In addition to 
MDM2, p53 can also be ubiquitinated by other ubiquitin ligases, such as COP1, PirH2, 
synoviolin, ARF-BP1, CARP1, CARP2, BAG-2, CHIP and β-TrCP (Chen et al., 2005; 
Rajendra et al., 2004; Yang et al., 2007, reviewed in Boehme and Blattner, 2009). 
Apart from its regulation by ubiquitin-modification, p53’s stability is also regulated 
by other small ubiquitin-like proteins, such as SUMO (small ubiquitin-like modifier) 
(Rodriguez et al., 1999)  and NEDD8 (ubiquitin-like modifier) (Xirodimas et al., 
2004). Since these modifications are also attached to p53 via lysines, they can inhibit 
p53 ubiquitination by competing with the same lysine. The stability of p53 is 
furthermore regulated by phosphorylation, acetylation and methylation (Chehab et al., 
2000; Sakaguchi et al., 2000; Schon et al., 2002; Shieh et al., 2000). However, several 
of these modifications impact on p53 stability only under experimental condition 
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while their role in a physiological setting is not entirely solved. 
The stability of the p53 protein is also controlled by its association with proteins that 
have no enzymatic activity. These proteins are able to impinge on p53 stability by 
enhacing or reducing the abundance of enzymes that modify p53 or by altering the 
affinity between the p53 protein and the modifiying enzymes. Proteins like MIF, 
G3BP1 and G3BP2 reduce p53 protein degradation and cause its transcriptional 
inactivation by retaining p53 in the cytoplasm (Jung et al., 2008; Kim et al., 2007). 
Others like ING1b, S100b and ATF3 disrupt the interaction between p53 and MDM2,  
and decrease ubiquitinylation of p53, (Fernandez-Fernandez et al., 2005; Leung et al., 
2002; Yan et al., 2005). Another notable example is MDMX, a homologe of MDM2 
but with no intrinsic ubiquitin ligase activity. MDMX is able to increase or decreease 
p53’s abundance depending on the conditions. MDMX can heterodimerize with the 
MDM2, and further elevate ubiquitinylation of p53.(Tanimura et al., 1999). But, 
MDMX can also competitively bind to the N-terminal domain of the p53 protein thus 
preventing MDM2 mediated ubiquitination and degradation (Barboza et al., 2008; 
Jackson and Berberich, 2000).  
1.5.2 The regulation of p53 activity. 
p53 is a transcription factor that is recruited to responsive elements of target genes 
upon cellular stress (McLure and Lee, 1998). Other reports show that p53 occupies 
the promoter region of target genes regardless of an activating stimulus (Kaeser and 
Iggo, 2002). If this observation is correct, then p53 may require additional activation 
steps to be able to trigger gene transcription. One possibility for activating 
pre-existing p53 molecules at chromatin is to post-translationally modify the protein. 
Many PTMs including phosphorylation, acetylation and methylation within the N- 
and C-terminal domain of p53 have been shown to enhance the affinity of p53 for its 
responsive elements in response to DNA damage, (Chuikov et al., 2004; Gu and 
Roeder, 1997; Meek, 1999). Phosphorylation of serine-15, for example, which is 
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implemented in response to double strand breaks, promotes its transcriptional activity 
by recruiting transcriptional coactivators (Lambert et al., 1998). Mutation of serine 15 
therefore reduces the anti-proliferative activity of p53 (Fiscella et al., 1993). 
Phosphorylation of Serine 392 of p53 is increased in response to UV exposure (Keller 
and Lu, 2002). This phosphorylation also increases tetramer formation and promotes 
p53’s export into the cytoplasm (Kim et al., 2004; Sakaguchi et al., 1997). Acetylation 
of p53 at lysine 379 is one of the most important acetylation sites. This modification 
requires phosphorylation at the N-terminal domain of p53 which then recruits 
p300/CBP to the C-terminal domain (Lambert et al., 1998). The C-terminal domain of 
the p53 protein is furthermore methylated by the Set9 methyltransferase. Methylated 
p53 is restricted to the nucleus and its stability is increased (Chuikov et al., 2004).  
Apart from PTMs, p53 activity is also regulated by protein-protein interactions. 
Notable examples are MDM2 and MDMX, two important negative regulators of the 
p53 protein (Barak and Oren, 1992; Shvarts et al., 1996). Also several members of the 
family of tripartite motif proteins (TRIMs) were found to regulate p53’s activity. For 
instance, TRIM13 ubiquitinates MDM2 and leads to its degradation, which leads to 
the stabilization of p53 and induction of the apoptotic response (Joo et al., 2011). 
TRIM24 mediates the stabilization and degradation of p53 protein (Allton et al., 2009) 
and TRIM25 increases p53’s stability, while it inhibits p53’s transcriptional activity 
(Zhang et al., 2015).  
 
1.6 Similar and distinct functions of MDM2 and MDMX in 
the regulation of p53. 
The mouse double minute 2 homolog protein, MDM2, was first identified as the 
product of a gene amplified over 50-fold on double minute chromosomes that have 
been found in a 3T3-DM mouse cell line that has transformed spontaneously 
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(Cahilly-Snyder et al., 1987; Fakharzadeh et al., 1991). Later it was found that MDM2 
interacts with p53 and regulates p53 activity (Momand et al., 1992). This regulation is 
performed in two ways: first, MDM2 binds to the transactivation domain of the p53 
protein and inhibits p53’s transcriptional activity. (Momand et al., 1992); second, 
MDM2 is an E3 ubiquitin ligase with a RING domain (really interesting new gene) 
that ubiquitinates p53 (Honda et al., 1997). Ubiquitinated p53 can then be recognized 
by 26S proteasomes and degraded (Lam et al., 2002), or sequestrated in the cytoplasm 
(Geyer et al., 2000). Due to the striking p53-inhibiting effect, Mdm2 is regarded as an 
oncogene. In fact, MDM2 induces tumor formation in nude mice when it is 
overexpressed (Fakharzadeh et al., 1991). MDM2 and p53 are connected by a 
negative feedback loop as p53 transactivates MDM2 and translated MDM2 protein 
inhibits p53’s transcriptional activity (Lozano and Montes de Oca Luna, 1998; Piette 
et al., 1997). This negative feedback loop is essential for controlling p53’s activity and 
to prevent detrimental pathogenic effects upon excessive p53 activity. The importance 
of MDM2 and this regulatory feedback loop is demonstrated by the lethality of 
MDM2 knockout mice that die because of arbitrary high p53 activity. The lethality of 
MDM2 knockout mice is rescued when p53 and MDM2 are both knocked-out (Jones 
et al., 1995; Montes de Oca Luna et al., 1995).  
MDMX was identified as a binding partner of p53 by screening a mouse cDNA 
library (Shvarts et al., 1996). As a close homolog of MDM2, MDMX is another 
essential negative regulator of p53. Like MDM2, MDMX acts as an oncogene and 
induces tumor formation when it is overexpressed (Danovi et al., 2004). MDMX also 
inhibits p53’s transcriptional activity via binding to the transactivation domain of p53 
protein. This association of MDMX with p53’s transactivation domain also reduces 
p53 acetylation by p300/CBP, which further inhibits p53’s activity (Sabbatini and 
McCormick, 2002). However, in contrast do MDM2, MDMX has no intrinsic E3 
ubiquitin ligase activity and is therefore principally unable to degrade p53.  
It is currently unclear how MDM2 and MDMX work together to control p53 
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abundance and activity. Currently several models exist to explain their cooperation 
(Figure 1.3). One possibility is that MDM2 and MDMX regulate p53 in a synergistic 
manner. In this model, the formation of MDM2-MDMX heterodimer is vital for the 
E3 ubiquitin ligase of Mdm2 (Linares et al., 2003; Linke et al., 2008; Singh et al., 
2007). The second possibility is that MDM2 and MDMX regulate p53 in an 
antagonistic way. MDMX competetively binds to the N-terminal domain of p53 
protein, preventing MDM2 mediated ubiquitination and nuclear exportation (Barboza 
et al., 2008; Jackson and Berberich, 2000). The possibility is that MDM2 and MDMX 
regulate p53 in an independent manner. Studies have shown that a conditional 
knockout of either MDM2 or MDMX or both in the central nevous system induces 
embryonic lehality. However, the timing of the embryonic lethality induced by MDM2 
or MDMX knockout (KO) is distinct (Xiong et al., 2006). Furthermore, a conditional 
KO of MDM2 in smooth muscle cells caused embryonic lethaliy whereas MDMX KO 
did not show such a severe defect (Boesten et al., 2006).  
 
Figure 1.3 | Models of MDM2 and MDMX function. In the model of synergistic function, 
MDM2 and MDMX form a heterodimer to promote p53 degradation. In this model MDM2 and 
MDMX depend on each other for successful inhibition and ubiquitination of p53. In the model of 
antagonistic function binds MDMX competitively to the N-terminal domain of p53 and suppresses 
p53’s activity. This prevents MDM2-mediated ubiquitination and degradation of p53. In the model 
of independent functions play MDM2 and MDMX distinct roles in the regulation of p53.  
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1.7 Mutant p53 
The p53 gene is one of the most frequently inactivated genes in human cancers 
(Hollstein et al., 1991). Approximately 50% of human cancers have a mutation in the 
p53 gene leading to inactivation of its function or have lost the p53 gene completely 
( Soussi and Beroud, 2001). About 74% of tumor-derived p53 harbors missense-point 
mutations that result in a high-level expression of mutant p53 (mutp53), which is 
usually localized in the nucleus (Olivier et al., 2010). Crystal structure analysis, of 
some of the p53 mutations has shown that some of these mutants are no longer able to 
associate with DNA. These mutations are therefore called “contact mutants”. The 
most commonly changed residues in breast cancer R248Q and R273H belong to this 
class of p53 mutations. In contrast, R175H and Y220C substitutions generate p53 
“structural mutants”. Although the mutation itself is not in the p53/DNA interface, it 
distorts the structure of the DNA binding domain (DBD) under physiological 
conditions (Walerych et al., 2012). Careful biophysical studies in vitro uncovered a 
gradient in the extent of p53 DBD destabilization by the specific TP53 hotspot 
mutations (Bullock et al., 2000). Strikingly, while mutant p53 is no longer able to 
activate its usual target genes, there is accumulating evidence that mutant p53 
acquires novel activities, including distinct DNA-binding and transactivation 
properties. Indeed, many loci lacking p53-responsive elements are found to be 
regulated by mutant p53 (Chicas et al., 2000; Scian et al., 2004). For instance, mutant 
p53 binds to the promoter region of c-myc when it is associated with PTEN, CBP and 
NFY and stimulates the expression of the proto-oncogene (Huang et al., 2013). 
Mutant p53, moreover, binds preferentially and autonomously to G/C-rich DNA 
around transcription start sites of several genes, characterized by active chromatin 
marks (Quante et al., 2012). Binding of mutp53 to these G/C-rich DNA regions that 
are associated with a large set of cancer-relevant genes may be an initial step in their 
regulation by mutant p53. In addition, a couple of p53 mutants, although defective in 
specific DNA sequence binding, retain the capability to bind to non-B DNA structures 
with high affinity. These DNA structures are rich in repetitive elements and other 
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sequences with a high likelihood of adopting non-B DNA conformation. Various DNA 
structures are bound by the different p53 mutants, through distinct mechanisms and 
with different affinities (Gohler et al., 2005). 
In principle, mutant p53 within a cell might have three, not mutually exclusive, 
outcomes. Firstly, such a mutation will abrogate the tumor suppressor properties of 
the affected TP53 allele and reduce the capacity of the cell to mount a proper p53 
response (Sigal and Rotter, 2000). Secondly, since p53 is active as a tetramer, mutant 
p53 can have a dominant-negative effect over wild-type p53 by forming mixed 
tetramers that are incapable of DNA-binding and transactivation. Therefore, even if 
one WT allele is retained, the cell may be rendered practically devoid of p53 function, 
particularly since the mutant protein is usually more stable and therefore present in 
excess over the wild-type counterpart (Michalovitz et al., 1991). Thirdly, mutant p53 
possesses activities of its own that are often not present in the original wild-type p53 
protein and that can actively contribute to the various aspects of tumor progression 
(Lanyi et al., 1998; Roemer, 1999). Such an activity is commonly described as mutant 
p53 gain-of-function (GOF).  
An ocean of GOF properties were demonstrated and a variety of underlying 
mechanisms were proposed after the discovery of the oncogenic potential of mutant 
p53 (Dittmer et al., 1993; Kim and Deppert, 2004; Shaulsky et al., 1991; Sigal and 
Rotter, 2000). A pivotal GOF mechanism is the ability of mutant p53 to bind and 
inactivate the other p53 family members, p63 and p73 (Di Como et al., 1999; Gaiddon 
et al., 2001). These transcription factors have a key role during development in 
addition to their pro-apoptotic activities (Deyoung and Ellisen, 2007). These p53 
family members can at least partially compensate the deletion of p53 because 
p53
+/-
p63
+/-
 mice and p53
+/-
p73
+/-
 mice have reduced survival and show increased 
metastasis after tumour induction in comparison to p53
+/-
 mice (Flores et al., 2005). 
Another GOF mechanism is the association of mutant p53 with other transcription 
factors that bind sequence-specific to target genes and regulate gene transcription. The 
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association with mutant p53 augments or attenuates the activities of these 
transcription factors. Well-investigated transcription factors that interact with mutant 
p53 are SP1 and ETS1 (Kim and Deppert, 2004). Most interestingly, the effects of 
wild-type and mutant p53 on SP1 and ETS1 are antagonistic (Kim and Deppert, 
2004). 
 
1.8 p53 isoforms 
The p53 protein is encoded by the TP53 gene, which comprises eleven exons, of 
which the first one is noncoding, and ten introns. It contains multiple genetic 
polymorphisms leading to more than one hundred distinct TP53 haplotypes. Some of 
these haplotypes are correlated with an increased risk of developing cancer (Dumont 
et al., 2003; Garritano et al., 2010; Wu et al., 2013). The first p53 isoforms were 
identified in the 1980s (Matlashewski et al., 1984; Wolf et al., 1985). In 1996, an 
alternatively spliced form of human p53 mRNA containing an additional 133bp exon 
derived from intron 9 was discovered. This splice variant encodes a truncated protein 
of 341 amino-acids that contains ten new amino-acids that are derived from the novel 
exon. The truncated protein, which lacks part of the p53 tetramerization domain, fails 
to bind DNA in vitro (Flaman et al., 1996). Today twelve isoforms are known that are 
encoded by the p53 gene (Bourdon et al., 2005; Courtois et al., 2002; Flaman et al., 
1996; Yin et al., 2002).  
As I described in Section 1.3, p53, comprises 393 amino acids and this isoform is 
named p53, FLp53, p53α or TAp53α; Figure 1.4). Other p53 isoforms are the result of 
alterative splicing, alternative promoter usage and alternative initiation of translation 
(Marcel et al., 2011). The proximal promoter (P1) controls the expression of the p53 
isoforms p53α, p53β and p53γ) as well as the isoforms that lack the first 40 amino 
acids (Δ40p53α, Δ40p53β, Δ40p53γ; Figure 1.4). The internal promoter (P2) controls 
the expression of the p53 isoforms that lack the first 133 amino acids (Δ133p53α, 
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Δ133p53β, Δ133p53γ) and the isoforms that lack the first 160 amino acid (Δ160p53α, 
Δ160p53β, Δ160p53γ) (Figure 1.4). The complete exclusion of intron 9 generates the 
canonical p53 isoform (α isoforms) while partial retention of intron 9 endows the -β 
and –γ isoforms. The β isoforms entirely replaced the tetramerisation domain and the 
regulatory domain by fifteen new amino acids (Marcel et al., 2011).  
 
Figure 1.4 | p53 isoforms encoded by the human p53 gene. A. Schematic drawing of the human 
p53 gene. The human p53 gene is composed of eleven exons. Transcription driven by two 
different promoters (P1 and P2) and alternative splicing at splicing sites i2 and i9 give rise to four 
different translation initiation sites (ATG1, ATG40, ATG133, ATG160). B. Domain structure of the 
different p53 isoforms. TAD1: transactivation domain 1 (amino acid 1-42), TAD2: transactivation 
domain 2 (amino acid 43-63), PXXP: proline rich domain (amino acid 64-92), DBD: DNA 
binding domain (amino acid 102-306), NLS: nuclear localization signal (amino acid 316-325), OD: 
oligomerization domain (amino acid 307-355) REG: regulatory domain (amino acid 364-393). 
MW: molecular weight; kD: kilo Dalton. (Surget et al., 2013, with modifications). 
The tetramerization domain and the C-terminal regulatory domain of p53 are 
important for the regulation of the subcellular localization of p53, which affects p53 
activity. In addition, this area contains ubquitination sites for most of those E3 ligases 
that modify p53 and is thus important for p53 stability (Boehme and Blattner, 2009). 
The absence of the tetramerization and regulatory domains furthermore alters the 
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choice for target genes. p53β, for instance, which lacks the last sixty amino acids of 
full length p53 while ten other amino acids have been added binds preferentially to 
the bax promoter but binds poorly to the MDM2 promoter (Bourdon et al., 2005). 
Likewise, p53γ that also lacks the last sixty amino acids of full length p53 while it has 
fifteen new amino acids, strongly binds to the bax promoter, but not to the p21 
promoter (Bourdon et al., 2005). p53 isoforms can furthermore affect the activity of 
full length p53. The Δ40p53α isoform, for example, which is generated by alternative 
splicing of intron 2, and lacks the first forty amino acids and thus most of the 
transactivation domain, has a dominant-negative effect over p53 and inhibits its 
transcriptional activity and impairs p53-mediated growth suppression (Courtois et al., 
2002). Δ40p53α furthermore affects ubiquitination and subcellular localization of full 
length p53 (Ghosh et al., 2004). Interestingly, mice heterozygous for the Δ40 isoform 
(p53/Δ40p53) are less susceptible to cancer than heterozygote p53+/− mice. However, 
mice homozygous for the Δ40 isoform (Δ40p53/Δ40p53) are as cancer prone as 
p53
−/−
 mice and do not show any accelerated aging, indicating that the accelerated 
aging phenotype may depend on the interplay between Δ40p53 and wild-type p53 
(Maier et al., 2004; Tyner et al., 2002). 
While the human isoforms of p53 are quite well investigated, less is known about 
these isoforms in mice. The use of the two promoters P1 and P2 yet appears to be 
conserved as well as the alternative splicing leading to the Δ40 and Δ160 isoforms 
(Δ157 in mice; Marcel et al., 2011). Yet the absence of the oligomerization domain 
and the regulatory domain, giving rise to the γ isoform that has not been found as yet 
in mouse cells and also the Δ133 isoform has not been described as yet. Instead, in 
mouse fibroblasts, another p53 isoform has been found that is generated by alternative 
splicing using a cryptic 3’ splicing site of exon eleven, giving rise to the p53 AS 
isoform (Figure 1.5, Wolf et al., 1985). Several papers reported that p53 and p53AS 
bind both to the responsive element of p53 but have distinct biochemical activities 
and are functional different. For instance, in contrast to p53 which binds poorly to 
DNA in vitro, the p53AS protein has a much higher affinity for DNA (Miner and 
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Kulesz-Martin, 1997; Wolkowicz et al., 1995; Wu et al., 1994).  
The different isoforms of murine p53 can be detected by an isoform-specific antibody 
(SAPU) that recognizes to the N-terminal and C-terminal domain of p53 (Marcel et al., 
2013). 
 
Figure 1.5 | p53 isoforms encoded by the mouse p53 gene. A. Schematic drawing of the p53 
gene showing the 11 exons and 10 introns and the two active promoters (P1) and (P2). The 
alternative splicing of intron 2 (i2) and the internal promoter (P2) are marked in red. Alternative 
splicing of the C-terminus generates the AS isoforms where the C terminal domain is replaced 
with 17 new amino acids (p53AS, Δ157p53AS, Δ40p53AS). B. Schematic drawing of the different 
isoforms. p53 and p53AS genes are transcribed from promoter P1 and contain the transactivation 
domain and the proline-rich domain. Δ157p53 andΔ157p53AS are truncated isoforms that are 
transcribed from the internal promoter P2 and that lack the transactivation domain as their 
translation is initiated at ATG-157. Δ40p53 and Δ40p53AS are transcribed from promoter P1, yet 
truncated due to alternative initiation of translation. Translation is initiated at ATG-41 and the 
proteins still contain part of the transactivation domain. The amino acid sequence in the 
C-terminal end is written in red and purple (AS). Molecular weights (kD) of the different p53 
isoforms are indicated. TAD+Pr: transactivation domain and proline rich domain; DBD: DNA 
binding domain; NLS: nuclear localization domain; OD: oligomerization domain. C. Binding sites 
of the isoformspecific anti-p53 antibody SAPU. (Marcel et al., 2013; with modifications).  
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1.9 p53 in stem cells. 
Embryonic stem cells (ESCs), the cell type derived from the inner cell mass of a 
blastocyst, hold the potential that differentiate into all three germ layer of an embryo 
(Evans and Kaufman, 1981; Martin, 1981). Owing to the ability of differentiating into 
all kinds of cell types, ESCs have developed mechanisms to adapt to various cellular 
stress, in particular DNA damage insults, to avoid passing the mutation to their 
progeny cells (Cervantes et al., 2002). As a guardian of the genome, p53 plays a 
crucial role in maintaining the integrity of genetic information (Lane, 1992). In 
embryonic stem cells, p53 exerts an important function in maintaining genomic 
stability and regulating differentiation, DNA repair and apoptosis (Li and Huang, 
2010; Lin et al., 2005). Like differentiated cells, stem cells activate a p53-dependent 
stress response (Solozobova et al., 2009). Thus, inhibition of p53 activity by treatment 
of cells with pifithrin-α, a small molecule inhibitor of p53, or shifting a 
temperature-sensitive mutant of p53 to the non-permissive temperature, reduces 
apoptosis in mESCs (Lee et al., 2005; Sabapathy et al., 1997). However, while ESCs 
are capable of inducing apoptosis in response to DNA damage, they lack the 
p53-dependent G1/S checkpoint in response to DNA damage (Aladjem et al., 1998). 
In comparison to differentiated cells, ESCs have two unique properties regarding their 
response to DNA damage that are regulated by p53. In the first place, ESCs are more 
sensitive to DNA damaging agents than somatic cells (Cervantes et al., 2002). 
Secondly, p53-dependent repression of Nanog and Oct3/4 leads to the differentiation 
of mESCs that have been exposed to DNA damage (Lin et al., 2005; Qin et al., 2007).  
Apart from the notion that p53 maintains the genome integrity of ESCs, a number of 
studies substantiate the finding that p53 is highly expressed in ESCs (Sabapathy et al., 
1997; Solozobova and Blattner, 2010).  
In addition to ESCs, p53 also plays a key role in adult stem cells (ASCs), For example, 
p53 regulates epithelial-mesenchymal-transition (EMT) in the mammary gland. EMT 
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and the reversed processes mesenchymal-epithelial-transition (MET) are key process 
for the regulation of embryogenesis. p53 suppresses EMT by binding to the promoter 
region of the microRNA miR-200c and elevating its transcription level (Chang et al., 
2011).  
Besides the regulation of differentiation and apoptosis in ESCs, p53 also serves as a 
barrier for the generation of iPSCs. A series of reports demonstate that inhibition of 
p53-regulated apoptosis pathway increase the efficiency of iPSC generation 
significantly (Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009; Marion et al., 
2009). However, the process of reprogramming by inhibition of p53 expression 
remains obscure because p53 will be required to eliminate damaged and unhealthy 
iPS cells and their progeny.  
 
1.10 Aim of this project.  
Despite the high abundance of the anti-proliferative p53 protein, mESCs have a high 
proliferation rate. A potential reason for this caveat is that p53 shows a predominantly 
cytoplasmic localization in stem cells while it is mostly nuclear in differentiated cells. 
The primary aim of this project was therefore:  
(1) To elucidate whether p53 indeed has a cytoplasmic localization in stem cells or 
whether this is just a question of the ratio of cytoplasm and nucleus, which is 
different in stem cell, and differentiated cells. 
(2) To find out how stem cells can survive despite expressing such a high amount of 
p53. E.g. to see whether p53 is differently modified in mESCs and/or differently 
associated with other protein,  
(3) To investigate the ultimate function of p53 in mESCs. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals 
Chemical Source 
Acetic acid Merck, Darmstadt 
Acetone Roth, Karlsruhe 
Ammonium persulfate (APS) Sigma-Aldrich, Taufkirchen 
Agar Nordwald, Erlangen 
Agarose  PeqLab, Erlangen 
Ampicillin, sodium salt Roth, Karlsruhe 
Aproptinin Sigma-Aldrich, Taufkirchen 
β-mercaptoethanol Roth, Karlsruhe 
β-mercaptoethanol for cell culture Invitrogen, Karlsruhe 
Bovine serum albumin (BSA) PAA, Cölbe 
Bromophenol blue Sigma-Aldrich, Taufkirchen 
Deoxyribonucleic acid sodium salt from 
salmon testes 
Sigma-Aldrich, Taufkirchen 
Dimethylsulfoxide (DMSO) Roth, Karlsruhe 
6×DNA loading dye PeqLab, Erlangen 
dNTPs Roche, Mannheim 
Draq5 BioStatus Limited, Shepshed (UK) 
Dithiothreitol (DTT) Sigma-Aldrich, Taufkirchen 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Invitrogen, Karlsruhe 
GlutaMAX Dulbecco’s Modified Eagle 
Medium (GlutaMAX DMEM) 
Invitrogen, Karlsruhe 
Formaldehyde Merck, Darmstadt 
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EDTA 25 mM Fermentas, St. Leon-Roth 
Ethylenediamine tetra-acetic acid (EDTA) Roth, Karlsruhe 
Ethanol Roth, Karlsruhe 
Etoposide (Eto) Sigma-Aldrich, Taufkirchen 
Fast Red TR Salt Sigma-Aldrich, Taufkirchen 
Fetal Bovine Serum (FBS) PAA, Cölbe 
Fetal Bovine Serum for mES cells (FBS) PAN-Biotech GmbH, Aidenbach 
Glycerol Roth, Karlsruhe 
Glycine Roth, Karlsruhe 
HEPES Roth, Karlsruhe 
HYDROMOUNT
TM
  
National diagnostics, Hessisch 
Oldendorf 
ImmunoPureR Immobilized Protein A 
Pierce, Thermo Scientific, Rockford 
(USA) 
Isopropanol Roth, Karlsruhe 
Leptomycin B (LMB) Sigma-Aldrich, Taufkirchen 
Leupeptin Sigma-Aldrich, Taufkirchen 
Lithium chloride (LiCl)  
MACSfectin Miltenyi Biotec, Bergisch Gladbach 
Magnesium carbonate (MgCO3) Roth, Karlsruhe 
Magnesium chloride (MgCl2) Roth, Karlsruhe 
Methanol Roth, Karlsruhe 
N,N,N’,N’-Tetramethylethylenediamine 
(TEMED) 
Roth, Karlsruhe 
Naphthol AS-MX phosphate Sigma-Aldrich, Taufkirchen 
N-Ethylmaleimide (NEM) Sigma-Aldrich, Taufkirchen 
Nicotinamide (NA) Sigma-Aldrich, Taufkirchen 
Non-Essential Amino Acid (NEAA) Invitrogen, Karlsruhe 
Nonidet-P40 (NP-40) Roth, Karlsruhe 
NuPAGE
®
 Antioxidant Invitrogen, Karlsruhe 
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NuPAGE
®
 LDS Sample Buffer Invitrogen, Karlsruhe 
NuPAGE
®
 MOPS SDS Running buffer Invitrogen, Karlsruhe 
Nutlin-3a Sigma-Aldrich, Taufkirchen 
Penicillin/Streptomycin Invitrogen, Karlsruhe 
1,10-Phenanthtroline Sigma-Aldrich, Taufkirchen 
Phenylmethanesulfonyl fluoride (PMSF) Sigma Aldrich, Taufkirchen 
Phosphostop Phosphatase Inhibitor Cocktail 
Tablets 
Roche, Grenzach 
Phosphate buffered saline (PBS) Invitrogen, Karlsruhe 
Potassium chloride (KCl) Roth, Karlsruhe 
Potassium dihydrogen phosphate (KH2PO4) Roth, Karlsruhe 
Rotiphorese Gel 30: Acrylmide/bis- 
acrylamide 
Roth, Karlsruhe 
Roti
®
-Mark BI-Pink Roth, Karlsruhe 
Roti
®
-Quant (5×) Roth, Karlsruhe 
rRNasin RNase Inhibitor Promega, Mannheim 
Skimmed milk powder Saliter, Obergünzburg 
Sodium acetate (NaAc) Roth, Karlsruhe 
Sodium bicarbonate (NaHCO3) Roth, Karlsruhe 
Sodium chloride (NaCl) Roth, Karlsruhe 
Sodium dodecyl sulfate (SDS) Roth, Karlsruhe 
Sodium hydrogen phosphate (Na2HPO4) Roth, Karlsruhe 
Sucrose Roth, Karlsruhe 
Thio-urea Roth, Karlsruhe 
Trichloroacetic acid (TCA) Sigma-Aldrich, Taufkirchen 
Trichostatin A (TSA) Sigma-Aldrich, Taufkirchen 
Tris base Roth, Karlsruhe 
Triton X-100 Roth, Karlsruhe 
TRizol Invitrogen, Karlsruhe 
tRNA Sigma-Aldrich, Taufkirchen 
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Tryptone/Peptone Roth, Karlsruhe 
Tween 20 Roth, Karlsruhe 
Urea Roth, Karlsruhe 
 
2.1.2 Enzymes 
Enzyme Source 
DNase I Pierce, Karlsruhe 
M-MLV Reverse Transcriptase, RNase H(-) Promega, Mannheim 
RNase A Invitrogen, Karlsruhe 
RQ1 DNase I Promega, Mannheim 
0.25% Trypsin-EDTA Invitrogen, Karlsruhe 
GoTaq® G2 DNA Polymerase Promega, Mannheim 
 
2.1.3 Kits 
Kits Source 
RNeasy Mini Kit (RNA purification) Qiagen, Hilden 
Trans-Blot
®
 Turbo
TM
 RTA Midi 
Nitrocellulose Transfer Kit 
Bio-Rad, Müchen 
 
2.1.4 Oligonucleotides 
2.1.4.1 Primers for qRT-PCR 
MATERIALS AND METHODS 
28 
 
All primers were synthesized by Metabion (Martinsried). 
Name Sequence 
RT-akt1-forward 5'-TGC ATT GCC GAG TCC AGA A-3' 
RT-akt1-reverse 5'-CAG CGC ATC CGA GAA ACA-3' 
RT-igf2-forward 5’-CGT GGC ATC GTG GAA GAG T-3’ 
RT-igf2-reverse 5’-ACA CGT CCC TCT CGG ACT TG-3’ 
RT-c-jun-forward 5’-CGA GTA CTG AAG CCA AGG GTA CAC-3’ 
RT-c-jun-reverse 5’-TGA GAT CGA ATG TTA GGT CCA TGC-3’ 
RT-lef1-forward 5’-CCC ACA CGG ACA GTG ACC TA-3’ 
RT-lef1-reverse 5’-TGG GCT CCT GCT CCT TTC T-3’ 
RT-mdm2-forward 5’-TGG AGT CCC GAG TTT CTC TG-3’ 
RT-mdm2-reverse 5’-AGC CAC TAA ATT TCT GTA GAT CAT TG-3’ 
RT-c-myc-forward 5’-GTC GTA ATT CCA GCG AGA GAC A-3’ 
RT-c-myc-reverse 5’-CTC TGC ACA CAC GGC TCT TC-3’ 
RT-p21-forward 5’-CCT GAC AGA TTT CTA TCA CTC CA-3’ 
RT-p21-reverse 5’-CAG GCA GCG TAT ATC AGG AG-3’ 
RT-ribpo-forward 5’-GGA CCC GAG AAG ACC TCC T-3’ 
RT-ribpo-reverse 5’-GCA CAT CAC TCA GAA TTT CAA TGG-3’ 
2.1.4.2 Primers for chromatin-immunoprecipitation assay 
All primers were synthesized by Metabion (Martinsried). 
Name Sequence 
ChIP-akt1-forward 5’-CCA AGC CTC ACC CAT CTG A-3’ 
ChIP-akt1-reverse 5’-GCG TGG GAA GTG AAT CAG TTT-3’ 
ChIP-c-jun-forward 5’-TCC GAC AGA CTC CGC AAG-3’ 
ChIP-c-jun-reverse 5’-TGA GTC CTT ATC CGA CCT GAG-3’ 
ChIP-mdm2-forward 5’-CGA GAG GTG ACA GGT GCC-3’ 
ChIP-mdm2-reverse 5’-CAG GAC TTA GCT CCT CCG AC-3’ 
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ChIP-c-myc-forward 5’-GTA AGC ACA GAT CTG GTG G-3’ 
ChIP-c-myc-reverse 5’-TGG TAA GTC AGA AGC TAC GGA-3’ 
2.1.4.3 siRNA 
All siRNAs were synthesized by Eurofin MWG Operon (Ebersberg). 
Name Sequence 
MDM2 siRNA 5’- GGC AAA AAG CUG ACA GAG A -3’ 
MDMX siRNA 5’- AGA TTC AGT TGG TTA TTA A -3’ 
p53 siRNA 5’-GCA UGA ACC GGA GGC CCA U-3’ 
Control siRNA 5’-AAC CCC UUU UAA AAG GGG CCC-3’ 
 
2.1.5 Eukaryotic cells and cell lines 
Name Source and description 
mESCs Embryonic stem cells from a mouse of the D3 strain 
Diff. cells mESCs induced to differentiate by incubation with retinoic 
acid for 7 days 
Feeder cells Mouse embryonic fibroblasts that have been irradiated with 
6.3 Gray of ionizing radiation 
MEF p53
+/+
 Mouse embryonic fibroblasts  
MEF p53
-/-
 Embryonic fibroblasts from a mouse with a homozygous 
deletion of the p53 gene 
p53
-/-
 mESCs Embryonic stem cells from a mouse of the D3 strain with a 
homozygous deletion of the p53 gene 
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2.1.6 Antibodies 
2.1.6.1 Primary antibodies 
Primary 
antibodies 
Description Source 
α7 (MCP72) Mouse, monoclonal Enzo Life Sciences GmbH, Lörrach 
Acetyl-p53 (Lys379) Rabbit, polyclonal Cell Signaling, Danvers (USA) 
β-actin Mouse, monoclonal Abcam, Cambridge (UK) 
β-actin (I-19) Goat, polyclonal Santa Cruz, Heidelberg 
Bax Rabbit, polyclonal Cell Signaling, Danvers (USA) 
GAPDH (6C5) Mouse, monoclonal HyTest, Köln 
Histone H3 (C16) Goat, polyclonal Santa Cruz, Heidelberg 
c-Jun (H79) Rabbit, polyclonal Santa Cruz, Heidelberg 
MDM2 (4B2) Mouse, monoclonal Calbiochem, Merck, Darmstadt 
MDMX (82) Mouse, monoclonal Sigma-Aldrich, Taufkirchen 
Nanog (C4) Mouse, monoclonal Santa Cruz, Heidelberg 
Oct3/4 (C10) Mouse, monoclonal Santa Cruz, Heidelberg 
p53 (1C12) Mouse, monoclonal Cell Signaling, Danvers (USA) 
p53 (PAb246) Mouse, monoclonal Millipore, Schwalbach 
p53 (PAb421) Mouse, monoclonal Millipore, Schwalbach 
p53 (CM5) Rabbit, polyclonal Vector-Lab., Peterborough (UK) 
PARC (PO69) Mouse, monoclonal BioLegend, Fell 
PCNA (PC10) Mouse, monoclonal Santa Cruz, Heidelberg 
Phospho-p53 (Ser6) Rabbit, polyclonal Cell Signaling, Danvers (USA) 
Phospho-p53 (Ser15) Rabbit, polyclonal Cell Signaling, Danvers (USA) 
Phospho-p53 (Ser392) Rabbit, polyclonal Cell Signaling, Danvers (USA) 
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2.1.6.2 Secondary antibodies 
Secondary antibodies Source 
Goat anti mouse IgG/HRP Dako, Glostrup (Dennmark) 
Goat anti rabbit IgG/HRP Dako, Glostrup (Dennmark) 
Sheep anti goat IgG/HRP Dako, Glostrup (Dennmark) 
Alexa Fluor 488 goat anti-mouse IgG (H+L) Invitrogen, Karlsruhe 
Alexa Fluor 488 goat anti-rabbit IgG (H+L) Invitrogen, Karlsruhe 
 
2.1.7 Size standards 
Name Source 
PeqGOLD Protein Marker IV PeqLab, Erlangen 
PeqGOLD 100bp DNA-Ladder Plus PeqLab, Erlangen 
 
2.1.8 Instruments and consumables 
Name Source 
Amersham ECL Hyperfilm GE Healthcare, Freiberg 
Analytical balance Mettler Toledo, Gießen 
Bioruptor
®
 sonication device Diagenode, Liège (Belgium) 
Blotting Filter Paper Bio-Rad, Müchen 
Cell culture incubator Heraeus, Fellbach 
Cell culture plastic ware (flask and dishes) Greiner Bio-One, Frickenhausen 
Clean bench W. H. Mahl, Trendelburg 
Cold room (4
o
C) Foster, Schutterwald 
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Cold room (-20
o
C) Foster, Schutterwald 
Cooling centrifuge Biofuge PrimoR for 
15/50 ml falcons 
Heraeus, Fellbach 
Cooling centrifuge Eppendorf 5417 R for 
PCR tubes 
Eppendorf, Hamburg 
Cooling microcentrifuge Heraeus 
Fresco17 
Thermo Scientific, Waltham (USA) 
Corex
®
 Centrifuge Tubes Corex (USA) 
Covaris
TM
 S220 focused ultrasonicator Thermo Scientific, Waltham (USA) 
Electrophoresis equipment (SDS-PAGE) Bio-Rad, Müchen 
Electrophoresis Power Supply PeqLab, Erlangen 
ELx 808IU Ultra Microplate Reader Bio-Tek Instruments, Bad Friedrichshall 
End-over-end rotator Heidolph, Schwabach 
Eppendorf tubes (1.5 ml and 2 ml) Eppendorf, Hamburg 
Ettan IPGphor II Isoelectric Focusing 
system 
GE Healthcare, Freiberg 
Falcons (15 ml and 50 ml) Greiner Bio-One, Frickenhausen 
Floor centrifuge Beckman Avanti J-20 Beckman Coulter, Krefeld 
Freezer (-20
 o
C) Liebherr, Ochsenhausen 
Freezer (-80
 o
C) 
New Brunswick Scientific, Edison 
(USA) 
Glass pipettes Brand, Wertheim 
Glassware (Erlenmeyer flasks, beakers, 
bottles) 
Scott, Mainz 
Hamilton syringe Hamilton, Martinsried 
High speed floor centrifuge Avanti J2-HS Beckman Coulter, Krefeld 
Horizontal nucleic acid electrophoresis 
system 
Bio-Rad, München 
Immun-Blot
®
 PVDF membrane Bio-Rad, Müchen 
Ink Pelikan, Hannover 
Inverted microscope Leica, Wetzlar 
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KODAK X-OMAT 2000 X-ray film 
processor 
Kodak, Stuttgart 
Laboratory balance Sartorius, Göttingen 
Magnetic stirrer IKA Labortechnik, Stauffen 
Measuring cylinders (10 ml, 25 ml, 50 ml, 
100 ml, 250 ml, 500 ml, 1000 ml, 2000 
ml) 
Brand, Wertheim 
Microcentrifuge Heraeus Pico 21 Thermo Scientific, Waltham (USA) 
NanoDrop ND-1000 Spectrophotometer Marienfeld, Lauda-Königshofen 
Neubauer counting chamber Marienfeld, Lauda-Königshofen 
NuPAGE
® 
10% Bis-Tris polyacrylamide 
gel 
Invitrogen, Karlsruhe 
Parafilm M Brand, Wertheim 
PCR thermocycler Bio-Rad, München 
96-well PCR plate and q-PCR clear seal Steinbrenner, Wiesenbach 
Petri dishes Greiner Bio-One, Frickenhausen 
Pipettes (2-20μl, 20-200μl, 200-1000μl) Gilson, Middleton (USA) 
Pipette Aid Brand, Wertheim 
Pipette tips Brand, Wertheim 
Platform shaker Heidolph, Schwabach 
Real-time PCR System StepOnePlus Applied Biosystems, Darmstadt 
Refrigerator (4
 o
C) Liebherr, Ochsenhausen 
Shaker for Eppendorf tubes Eppendorf, Hamburg 
Syringes and needles B. Braun, Melsungen 
Test-tube rotator Kisker, Steinfurt 
Thermomixer Eppendorf, Hamburg 
Trans-Blot
®
 Turbo
TM
 Transfer System Bio-Rad, München 
UV transilluminator PeqLab, Erlangen 
Vortexer Julabo, Seelbach 
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2.1.9 Software 
Name Version/Description 
Bowtie V 0.12.7 
CASAVA V 1.8.1 
Filezilla V 3.9.0.2 
HTSeq V 0.5.3p3 
ImageJ V 1.45s 
Primer Primier V 5.0-64bit 
R  DESeq 
TOPHAT V 1.4.1 
Zeiss LSM Image Browser V 4.2.0.121 
 
2.1.10 Data Base 
Name Source 
Ensembl Release 67 Ensembl 
Mouse genome M37 NCBI 
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Cultivation of mouse embryonic fibroblasts  
The p53
+/+
 and p53
-/-
 mouse embryonic fibroblasts (MEFs) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (PAA) and 1% penicillin/streptomycin (Invitrogen) at 37
o
C in 5% CO2 and 90% 
humidity. When the cells reached 80-90% confluence, they were trypsinized and 
subcultured in a new cell culture flask. For trypsinization, the cell culture medium 
was aspirated, and the cells were washed once with PBS (Invitrogen). Then the cells 
were incubated with trypsin-EDTA (Invitrogen) at 37
o
C until they were detached from 
the cell culture dish. The trypsinization was stopped by addition of five volumes of 
complete growth medium. The cells were pelleted at 1,200 rpm for 2 minutes. The 
supernatant was aspirated and the cell pellet was suspended in complete cell culture 
medium. A desired number of MEFs were transferred into a new cell culture flask.  
2.2.1.2 Preparation of feeder cells  
2.2.1.2.1 Isolation of primary embryonic fibroblasts 
Prior to the isolation of mouse embryonic fibroblasts, the surgical instruments were 
autoclaved. During the isolation process, the instruments were kept in 70% ethanol. 
A pregnant mouse was sacrificed 13.5 days postcoitum by cervical dislocation (done 
by Selma Huber). The body of the mouse was opened and the uterine horns were 
dissected and transferred into a sterile petri dish containing sterile PBS. The embryos 
were peeled from the placenta and surrounding tissue with forceps and each embryo 
was placed into a new sterile petri dish containing PBS. The embryo was separated 
from yolk and the head, tail and liver were removed. The rest of the embryo was 
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transferred into a 15 ml-reaction tube and chopped with a blade until no large pieces 
of tissue were visible anymore. The chopped embryos were incubated with 2 ml 0.25% 
Trypsin-EDTA at 37
o
C for 10-15 minutes. The trypsin was inactivated by addition of 
4 ml complete cell culture medium and the larger pieces were separated from single 
cells and small cell clumps by sedimentation for 5 minutes. The supernatant 
containing single cells was carefully aspirated and transferred into a new 15 
ml-reaction tube. Then the cells were collected by centrifugation at 1,200 rpm for 5 
minutes. The cell pellet was suspended in 10 ml of cell culture medium and 
transferred into a 10 cm cell culture petri dish. The cells were cultured at 37
o
C and 5% 
CO2 in a humidified cell culture incubator.  
2.2.1.2.2 Amplification of primary fibroblasts 
When the fibroblasts reached 80-90% confluency, the cells were passaged at a ratio of 
1:6 (P1 cells) and incubated at 37
o
C with 5% CO2 and 90% humidity or frozen in 
liquid nitrogen. When the cells reached again 80-90% confluency, the cells were 
splitted again at a ratio of 1:6 (P2) and cultured until they reached 80-90% confluency. 
Then the cells were splitted a third time (P3). When the cells reached 80-90% 
confluency, they were irradiated for mitotic inactivation. 
2.2.1.2.3 Mitotic inactivation of MEFs with γ-irradiation 
The fibroblasts were harvested by trypsinization. Trypsinization was stopped by 
addition of complete DMEM medium. The cell number was determined and the cells 
were pelleted by centrifugation at 1,200 rpm for 5 minutes. The cell pellet was 
suspended in the desired volume of complete DMEM cell culture medium and the 
cells were irradiated with 7.5 Gray at a dose rate of 0.5 Gray/minute by using a 
60cobalt γ-source. After irradiation, the cell suspension was aliquot into freezing tubes. 
10% DMSO were added and frozen in liquid nitrogen. For culturing mESCs, the 
feeder cells were thawed and plated at a density of 9.1×10
5
 mitotic inactive cells per 
50mm cell culture dish.  
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2.2.1.3 Cultivation of mouse embryonic stem cells  
D3 and p53
-/-
 mouse embryonic stem cells (mESCs) were cultured in GlutaMAX 
Dulbecco’s Modified Eagle Medium (GlutaMAX-DMEM, Gibco) supplemented with 
15% fetal bovine serum (PEN-Bio), 100×non-essential amino acids (NEAA, 
Invitrogen), 1% penicillin/streptomycin (Invitrogen), 0.1mM β-mercaptoethanol 
(Invitrogen) and 1000 units/ml LIF on feeder cells at 37
o
C, 5% CO2 and 90% 
humidity. The medium was changed every day and cells were passaged every second 
day. For passaging, the cell culture medium was aspirated, and the cells were washed 
once with PBS (Invitrogen). Then the cells were incubated with trypsin-EDTA 
(Invitrogen) at 37
o
C until they were detached from the culture dish. The trypsinization 
was stopped by addition of five volumes of complete growth medium. The cells were 
pelleted by centrifugation at 1,200rpm for 2 minutes. The supernatant was aspirated 
and the cell pellet was suspended in fresh complete medium. 5×10
4
 cells were 
transferred into a 50mm cell culture dish containing 9.1×10
5
 feeder cells prepared as 
described in section 2.2.1.2.  
2.2.1.4 Treatment of cells with ionizing radiation and chemicals  
Cells were irradiated for 7.5 Gray with a 
60cobalt γ-source at a dose rate of 0.5 
Gray/minute in cell culture medium. 
Etoposide (Eto) was dissolved in DMSO and used at a final concentration of 50μM. 
The cells were incubated for 3 hours. 
Leptomycin B (LMB) was dissolved in ethanol and used at a final concentration of 
2μM. Cells have been serum-starved overnight prior to the addition of LMB and were 
incubated for 16 hours.  
Trichostatin A (TSA) was dissolved in DMSO and used at a final concentration of 
1μM. Cells were incubated for 6 hours.  
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Nicotinamide (NA) was dissolved in ddH2O and applied at a final concentration of 
5mM. Cells were incubated for 6 hours.  
Nutlin-3 was dissolved in DMSO and used at a final concentration of 5μM. Cells 
were incubated as indicated. 
2.2.1.5 Cell transfection with siRNA  
D3 and p53
-/-
 mESCs were transiently transfected with siRNA by using 
MACSfectin
TM
 (Miltenyi Biotec) according to the manufacturers recommendation. 
For transfection in 24-well plate, 1μg siRNA was diluted in GlutaMAX-DMEM w/o 
serum or antibiotic in a 1.5 ml polypropylene tube. 2μl of MACSfectin were diluted in 
another tube. After dilution and homogenized by pipetting, the siRNA and 
MACSfectin solutions were mixed by pipetting up and down for 3-5 times. The 
mixture was incubated for 20 minutes at room temperature (RT) to allow the 
formation of the transfection complex. In the meantime, the cells were trypsinized and 
collected by centrifugation at 1,200 rpm for 2 minutes. The cell pellets were 
suspended in complete GlutaMAX-DMEM and the cell number was determined. 
1×10
5
 cells were suspended in 400μl complete GlutaMAX-DMEM and plated into a 
24-well plate coated with 0.1% gelatin. 100μl of the transfection mixture were added 
dropwise to the cell suspension. The culture medium was changed the next day, and 
cells were harvested 48 hours after transfection.  
2.2.1.6 Differentiation of mESCs with retinoic acid  
mESCs were trypsinized and collected by centrifugation. The cell pellets were 
suspended in GlutaMAX-DMEM supplemented with 10% fetal bovine serum (PAA), 
100×non-essential amino acid (NEAA, Invitrogen), 1% penicillin/streptomycin 
(Invitrogen), 0.1mM β-mercaptoethanol (Invitrogen) and 1μM all-trans-retinoic acid. 
2×10
5
 p53
+/+
 mESCs or 8×10
4
 p53
-/-
 mESCs were seeded in a gelatin-coated 100mm 
cell culture dish and incubated at 37
o
C in 5% CO2 and 90% humidity for seven days. 
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The medium was refreshed every second day.  
2.2.1.7 Alkaline phosphatase staining  
mESCs were cultured on feeder cells in complete GlutaMAX DMEM medium for 48 
hours. The culture medium was removed, and the cells were washed with pre-chilled 
PBS and fixed with 4% PFA in PBS for 20 minutes at room temperature on a shaker. 
The PFA/PBS solution was removed and the cells were washed three times for 10 
minutes at RT with TM buffer (30mM Tris-HCl, 1M maleic acid, 1M NaOH, 
adjusting pH to 9.0). Then the cells were incubated with freshly prepared staining 
buffer (5ml TM buffer, 0.75mg Naphtol, 1.25mg Fast Red TR Salt) for 20 minutes at 
RT on a shaker. The cells were washed twice for 10 minutes with PBS and analyzed 
under a microscope.  
 
2.2.2 Proliferation assays 
2.2.2.1 Counting cells with a Neubauer chamber 
For counting the cells, the cells were trypsinized with 0.5ml trypsin. Trypsinization 
was stopped by adding 2ml complete GlutaMAX medium. 10μl of the cell suspension 
were pipetted into a Neuauer chamber that was covered with a cover slide. The cell 
number was determined by counting the blue labeled areas (N1-N4; Figure 2.1) under 
a microscope. The total cell number was calculated with the formula:  
Cell number per ml = (N1+N2+N3+N4)×10
4
/4 
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Figure 2.1 | Schematic picture of a Neuauer chamber. Shown is the center of a Neubauer 
chamber with the marks for counting the cells. The cells in the blue areas are counted. The number 
is then divided by four and multiplied by 1×10
4
. This gives the number of cells per ml.  
2.2.2.2 MTT assay 
After the cells had been incubated for a desired time, 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was dissolved in cell 
culture medium at a concentration of 5mg/ml (MTT solution). 150μl of this MTT 
solution and 250μl GlutaMAX complete cell culture medium were added to the cells. 
The cells were incubated at 37
o
C, in a humidified cell culture incubator for 4 hours. 
Then the medium was removed, and the cells and the formazan salt were solubilized 
in 1.5 ml isopropanol. 150μl of this solution were transferred onto a micro-plate and 
the absorbance of the solution was determined at λ595nm by a micro-plate ELISA 
reader. 
 
2.2.3 Immunofluorescence staining. 
For immunofluorescence staining, cover slips were autoclaved and scattered to a 
6-well plate. The cover slips were coated with 0.1% gelatin for at least 15 minutes. 
The gelatin solution was aspirated and feeder cells were plated onto the cover slips. 
24 hours after the feeder cells have been seeded, mESCs were plated onto the feeders 
in GlutaMAX-DMEM complete cell culture medium. 24 hours after plating of the 
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mESCs, the medium was aspirated and the cover slips with the cells were transferred 
into a 24-well plate. The slips were washed twice with pre-chilled PBS and fixed with 
ice-cold acetone/methanol (1:1) for 8 minutes on ice. Then the cover slips were 
washed three times with cold PBS and blocked for 30 minutes with blocking buffer (1% 
bovine serum albumin and 1% goat serum in PBS). After blocking, the cells were 
incubated overnight with primary antibodies. The next day, the cover slips were 
washed three times with cold PBS and incubated for 30 minutes in the dark with an 
antibody directed against mouse IgG coupled with Alexa-Fluro-488 (Invitrogen) or 
with an antibody directed against rabbit IgG coupled with Alexa-Fluro-488 together 
with Draq5. All reagents were diluted 1:1000 with blocking buffer. After incubation, 
the cover slips were washed three times with cold PBS and mounted with 
Hydromount onto microscope slides. The slides were prevented from light until they 
were analyzed by microscopy. 
 
2.2.4 Preparation of cell lysates 
Cells were rinsed once with ice-cold PBS and scraped in PBS. The cell suspension 
was transferred into an Eppendorf tube and cells were collected by centrifugation at 
10,000 rpm for 1 minute. The supernatant was removed and the cell pellet was 
suspended in NP-40 lysis buffer (150mM NaCl, 50mM Tris pH 8.0, 5mM EDTA pH 
8.0, 1% NP-40, 1mM PMSF). The samples were incubated on ice for 15 minutes and 
then centrifuged at 4°C for 10 minutes with 13,300 rpm to pellet insoluble fragments.  
2.2.4.1 Determination of the protein concentration of cell lysates. 
The protein concentration of cellular lysates was determined as described by Bradford 
(Bradford 1976). To enable the determination of the protein concentration, first a 
calibration curve was established. Therefore, Roti®-Quant was diluted 1:5 with 
ddH2O. Then 4μl lysis buffer were mixed with 500μl of the diluted Roti®-Quant 
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solution and 1, 2 or 4 µl of a solution of 1 mg/ml BSA in ddH2O. 150μl of these 
mixtures were transferred into a 96-well culture plate. The absorbance of the BSA 
mixtures was measured at 595nm in a micro-plate reader. For the standard curve, the 
values of the absorbance and the corresponding BSA protein concentration were 
plotted in a linear manner. Then 4μl of cell lysate were mixed with 500μl of the 
diluted Roti
®
-Quant solution and 150μl of this mixture were transferred into a 96-well 
plate. The absorbance of protein samples was determined by using a micro-plate 
reader. The protein concentration was calculated by using the standard curve. 
 
2.2.5 SDS PAGE 
Prior to the casting of the SDS-PAGE gel, the glass plates were cleaned and dried. A 
short glass plate was placed in front of a large glass plate, the bottom of the plates was 
placed accurately flat and the two plates were fixed by a casting frame and transferred 
to a casting stand. For the separating gel, 4.0ml ddH2O were mixed with 3.3ml 30% 
acrylamide mix, 2.5ml 1.5M Tris pH 8.8, 100μl 10% SDS, 100μl 10% APS and 4μl 
TEMED. The gel mixture was poured between the two glass plates, overlaid with 
absolute ethanol and allowed to polymerize at room temperature for 30 minutes. After 
polymerization, the ethanol was removed, the top of the gel was rinsed with ddH2O 
and dried with a tissue. The stacking gel consisting of 1.38ml ddH2O, 330μl 30% 
acrylamide mix, 250μl 1M Tris pH 6.8, 20μl 10% SDS, 20μl 10% APS and 2μl 
TEMED was poured over the separating gel. A comb was inserted into the stacking 
gel to create wells. After polymerization, the comb was removed, the gel was inserted 
into an electrophoresis chamber and the chamber was filled with 1×SDS running 
buffer (193mM glycine, 24mM Tris and 0.1% SDS). 
20-50g of protein were mixed with 20% of a 5×SDS loading buffer (400mM Tris pH 
6.8, 4% SDS, 20% glycerol, 4% β-mercaptoethanol and 0.001% bromophenol blue) 
and heated to 95
o
C for 5 minutes. A prestained protein marker, to enable a size 
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estimation of the separated proteins, and the boiled protein samples were loaded next 
to each other into the wells of the stacking gel. Electrophoresis was carried out at 
130V for approximately 2 hours until the bromophenol blue line reached the bottom 
of the gel.  
For the detection of p53 isoforms, the lysates were mixed with 25% of 4×NuPAGE
®
 
LDS Sample Buffer supplemented with 0.1M DTT and heated at 95
o
C for 5 minutes. 
20μg of protein were loaded on pre-casted NuPAGE® 10% Bis-Tris polyacrylamide 
gels (Invitrogen) and separated by using 1×MOPS Running Buffer (Invitrogen) 
supplemented with 0.2% antioxidant (Invitrogen) at 120V for 1h 15min.  
 
2.2.6 Western blotting and Immunodetection 
After electrophoresis, the proteins were transferred onto an Immun-Blot
®
 PVDF 
(Polyvinylidene difluoride) membrane using a Bio-Rad semi-dry Trans-Blot
®
 
Turbo
TM
 Transfer System. The Immun-Blot
®
 PVDF membrane was rinsed with 
absolute ethanol until the membrane became translucent. The ethanol was removed 
and the membrane was equilibrated in Trans-Blot Turbo Transfer Buffer for 
approximately 2-3 minutes. Two transfer stacks were immersed in a soaking tray 
containing 50-70ml of transfer buffer for 2-3 minutes. The transfer sandwiches were 
assembled according to the scheme provided in Figure 2.2. Excess transfer buffer was 
carefully removed by inverting the cassette base with the assembled stack.  
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Figure 2.2 | Layering of the western blot transfer pack. A membrane was laid in the center of 
the base of the ion reservoir stack (anode stack). Then the gel was aligned on the membrane. Air 
bubbles between the gel and the membrane were removed with a blot roller. The second ion 
reservoir stack (cathode stack) was then place onto the gel. Air bubbles in the assembled transfer 
stack were removed by a blot roller so that consistent contact was allowed between the layers. 
(Source: http://www.bio-rad.com/) 
Then the lid of the cassette was placed onto the base and the transfer was performed 
with 1.3A and up to 25V for 16 minutes. After the transfer, the membranes were 
immersed in 2% ink in TBS/0.2% Tween20 (TBST, 50mM Tris-Cl pH 7.6, 150mM 
NaCl and 0.2% Tween20) for 10 minutes to see whether the membrane was free of air 
bubbles. The membrane was rinsed twice with TBST and blocked with blocking 
buffer (5% skimmed milk powder in TBST (w/v)) for 1 hour. After blocking, the 
membrane was incubated overnight with the primary antibody diluted in 5% 
BSA/TBS (w/v). The next day, the membrane was washed three times for 5 minutes 
with TBST and incubated for 1-2 hours with an HRP-coupled secondary antibody 
diluted in 5% BSA/TBS (w/v). After incubation with the secondary antibody, the 
membrane was washed twice for 5 minutes in TBST and once for 10 minute in TBS. 
A mixture of equal volumes of ECL solution I and II (Pierce) was distributed evenly 
across the membrane and incubated at room temperature for I minute. The membrane 
was wrapped into cling film and exposed against an X-ray film (GE Healthcare) in the 
dark rom. The exposed X-ray film was developed by an X-ray film processor. 
2.2.7 Cell Fractionation 
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For performing cell fractionation, the cells were washed with ice-cold PBS, scraped 
from the culture dish and collected by centrifugation The supernatant was aspirated 
and the cell pellet was suspended in four packed cell volumes homogenization buffer 
(10mM HEPES pH 7.4, 50mM NaCl, 0.5M sucrose, 0.5% Triton X-100, 1mM PMSF), 
incubated on ice for 5 minutes and collected by centrifugation at 4
o
C with 1,000rpm 
for 10 minutes. The supernatant that contained the cytoplasmic fraction was carefully 
transferred into a new 1.5ml Eppendorf tube and kept on ice. The nuclei were washed 
twice with ice-cold PBS and suspended in the same volume of lysis buffer that was 
used to release the cytoplasmic fraction, disrupted by sonication with 400W for 20 
cycles (1 sec on/1 sec off) and kept on ice. Both fractions were used for performing 
SDS-PAGE (See section 2.2.5 and 2.2.6) or stored at -20
o
C.  
Alternatively, cells were washed, scraped into PBS and pelleted by centrifugation at 
4
o
C with 1,200 rpm for 5 minutes. The supernatant was aspirated and the cell pellet 
was re-suspended in a small volume of homogenization buffer (10mM HEPES pH 7.9, 
10mM KCl, 1.5mM MgCl2, 0.5mM DTT, 1×EDTA-free Protease Inhibitor Cocktail) 
and incubated on ice for 5 minutes. The nuclei were released by 15-25 strokes with a 
homogenizer and collected by centrifugation at 4
o
C with 300g for 5 minutes in. The 
supernatant containing cytoplasmic fraction was transfered into a new 1.5ml 
Eppendorf tube and kept on ice. The nuclei were suspended in 0.25M sucrose buffer 
(0.25M Sucrose, 10mM MgCl2, and 1×EDTA-free Protease Inhibitor Cocktail) and 
layered onto a cushion of 0.88M sucrose buffer (0.88M Sucrose, 0.5mM MgCl2, 
1×EDTA-free Protease Inhibitor Cocktail). The nuclei were collected by 
centrifugation at 4°C with 2,800g for 10 minutes. The supernatant was removed and 
the nuclei were lysed in lysis buffer (50mM Tris pH 8.0, 150mM NaCl, 5mM EDTA, 
1% NP-40, 1mM PMSF, 1×EDTA-free Protease Inhibitor Cocktail). Both fractions 
were used for performing SDS-PAGE (See section 2.2.5) or stored at -20
o
C.  
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2.2.8 Two-dimensional SDS PAGE 
Two-dimensional SDS PAGE was performed to separate proteins both by their 
molecular weight and by their isoelectric point (Figure 2.3).  
The medium was aspirated from the cells, the cells were washed once with cold PBS 
scraped from the culture dish, transferred to a reaction tube and collected by 
centrifugation. The supernatant was removed, the cells were suspended in Urea Lysis 
buffer (8.5M Urea, 4% CHAPS, 50mM Tris pH 8.0, 1mM PMSF) and disrupted by 
sonication for 10 seconds. The lysate was cleared by centrifugation at 4°C for 20 min 
with 13,300 rpm. The supernatant was transferred to a new 1.5ml Eppendorf tube and 
the protein concentration was determined as described above (See section 2.2.4). 1mg 
of the protein was diluted with an equal volume of 2×IEF buffer (5M Urea, 2M 
Thio-urea, 65mM CHAPS, 4mM tributylphosmin and 1% Carrier-ampholyte pH 3-11 
NL). The volume was adjusted to 335μl with Rehydration buffer (5M Urea, 2M 
Thio-urea, 65mM CHAPS, 2mM tributylphosmin, 0.5% Carrier-ampholyte pH 3-11 
NL). 5μl 0.8% (w/v) Brilliant Blue G in rehydration buffer were added, the sample 
was loaded onto a 18 cm Immobiline DryStrip pH 3-11 NL and allowed to soak 
overnight. 
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Figure 2.3 | Schematic picture of Two-D SDS PAGE. The proteins were first separated by their 
isoelectric point (pI, 1
st
 dimension). Then proteins were further separated by their molecular 
weight (MW, 2
nd 
dimension). The balls in distinct color represent proteins with distinct pIs. The 
size of the colored balls represents the different MWs of the proteins, big balls mean high MW 
proteins, and small balls mean low MW proteins.  
The next day, the protein was separated by isoelectric focusing. The stripe was placed 
in an Ettan IPGphor II Isoelectric Focusing system (GE Healthcare) and covered with 
mineral oil. Isoelectric focusing was performed at 25
o
C and 200V for 3.5 hours, at 
500V for 3.5 hours, at 1000V for 3.5 hours, at a gradient ramp up to 8000V for 1 hour 
and at 8000V for 11 hours. After separation in the first dimension by isoelectric 
focussing, the strips were rinsed with ddH2O to remove excess mineral oil. The IEF 
gel was equilibrated in equilibration buffer (50mM Tris pH 8.8, 6M urea, 30% 
Glycerol, 2% SDS) plus 65mM DTT for 15 min and alkylated for 15 min in 20mg/ml 
iodoacetamide in equilibration buffer containing 0.03% Commassie Brilliant Blue G 
in ddH2O. 12.5% SDS polyacrylamide gels (For 100ml solution: 33ml ddH2O, 40ml 
30% acrylamide mix, 25ml 1.5M Tris pH 8.8, 1000μl 10% SDS, 1000μl 10% APS 
and 40μl TEMED) were casted in the PROTEAN Plus Multi-Casting Chamber up to 1 
cm below the end of the small glass plate and overlaid with isopropanol. After the 
polymerization of the acrylamide mixture, the isopropanol was removed and the top 
of the gel was rinsed with ddH2O. The equilibrated gel strips from the isoelectric 
focusing were carefully laid onto the top of the polymerized polyacrylamide gel and 
immersed in 0.8% Commassie Brilliant Blue G in 1% (w/v) agarose. After the 
solidification of the agarose, the gels were transferred into the Ettan DALT large 
vertical system and the electrophoresis chamber was filled with a Tris-glycine buffer 
(193mM glycine, 24mM Tris and 0.1% SDS). Electrophoresis was performed at 2W 
per gel for 6 hours. After electrophoresis, the proteins were transferred onto a PVDF 
membrane by Western Blotting and detected by immunodetection as described (See 
section 2.2.6). 
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2.2.9 Sucrose gradient centrifugation  
Sucrose gradient centrifugation was performed to separate proteins and protein 
complexes under native condition. In the sucrose gradient, the particles travel through 
the gradient until they reach the layer where the density of the particles matches that 
of the surrounding sucrose. 
For the gradient, sucrose was dissolved in 25mM Tris pH 7.4, 50mM NaCl, 1mM 
PMSF to achieve a sucrose concentration of 10% and 40%. The two sucrose solutions 
were poured into a gradient mixer connected to a mini-pump that transferred the 
mixture into a polyallomer centrifuge tube. The gradient was kept on ice until it was 
used.  
To prepare the lysate, the medium was aspirated and the cells were washed twice with 
ice-cold PBS, scraped into PBS and collected by centrifugation at 13,300 rpm for 10 
seconds at 4°C. The cell pellet was suspended in lysis buffer (50mM Tris pH 7.4, 
20mM NaCl, 10mM MgCl2, 0.5% NP-40, 5mM ATP, 1mM DTT, 1mM PMSF, 
40U/ml DNase I, 10mM N-ethylmaleimide, 10mM 1,10-Phenanthtroline and 
1×Phosphostop), homogenized by pushing it 3 times through a 26G needle and 
incubated on ice for 30 min. The protein extract was cleared by centrifugation at 4
o
C 
with 13,300 rpm for 15 min. The protein concentration was determined and 2mg 
protein were loaded onto the sucrose gradient. The sucrose gradient was placed into a 
SW 50.1 rotor (Beckman) and centrifuged at 4 °C for 18 h with 37,000 rpm. After 
centrifugation, fractions were collected and analyzed by SDS PAGE and Western 
Blotting (see section 2.2.5 and 2.2.6). 
2.2.10 RNA sequencing 
2.2.10. 1 Extraction of total RNA from eukaryotic cells 
Total RNA was prepared using TRIzol according to the manufacturer’s instructions 
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Cells were washed with PBS, scraped in PBS and pelleted by centrifugation. TRIzol 
was added to the pellet and the mixture was homogenized by vortexing. The 
Homogenized samples were kept at room temperature for 5 minutes to permit 
complete lysis. 0.2ml chloroform were added per ml TRIzol, vortexed and incubated 
at room temperature for 3 minutes. The samples were centrifuged at 10,000 rpm for 
15 minutes to allow the different phases to separate. The aqueous phase that contained 
the RNA was carefully transfered into a fresh reaction tube, mixed with 0.5ml 
isopropanol per ml TRIzol and incubated on ice for 10 minutes to precipitate the RNA. 
The RNA was collected by centrifuged at 4°C with 10,000 rpm for 15 minutes. The 
supernatant was removed and the RNA was washed twice with 1ml 75% ethanol. 
Finally, the RNA was dissolved in RNase free water and handed over to our 
sequencing facility.  
2.2.10. 1 Analysis of the sequencing results 
The sequencing resulted in more than sixty-seven million reads per sample each of 
which being 50 nucleotides long with a mean Phred quality score over 35 and reading 
errors smaller than two to the minus thirty-five.  
The reads where then mapped against the mouse genome M37 database using the 
TOPHAT software (Trapnell et al., 2010). To see whether the fragment sequences 
belong to distinct exons, the BOWTIE software was applied. Finally, gene expression 
was determined using the HTSeq software (Anders and Huber, 2010). This software 
counted for each gene the number of reads. The software DESeq was then used to 
normalize the data (Figure 2.4; Anders and Huber, 2010).  
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Figure 2.4 | Scheme of RNA sequencing analysis. The reads were mapped against the mouse 
genome M37 database by applying the TOPHAT software. The exon junstions were determined 
using the BOWTIE software and the Ensembl release 67 database. Gene expression was 
determined with the HTSeq software and differential gene expression was determined using the 
DESeq software. 
 
2.2.11 Chromatin-immunoprecipitation and polymerase chain 
reaction 
Chromatin-immunoprecipitation (ChIP) was performed to detect p53 bound to 
promoters of target genes. 
2.2.11.1 Chromatin-immunoprecipitation (ChIP) 
Proteins and DNA were cross-linked by adding formaldehyde to the culture medium 
to a final concentration (f.c.) of 1% and incubation for 10 min at room temperature 
(RT) on a rocking platform. The reaction was stopped by addition of glycine (0.125M 
f.c.) and incubation for 5 min at RT. The media was removed and the plates were 
washed twice with ice-cold PBS. The supernatant was removed, the cells were 
scraped from the dish, collected by centrifugation and washed with cold PBS 
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containing 1mM PMSF. The cells were suspended in 3 volumes lysis buffer (5mM 
HEPES pH 8, 85mM KCl, 0.5% NP40, 1mM PMSF, 1µg/ml aproptinin, 1µg/ml 
leupeptin) and incubated on ice for 10 minutes. The nuclei were pelleted at 4°C for 5 
min with 5000 rpm, and suspended in nuclei lysis buffer (50mM Tris pH 8.1, 10mM 
EDTA pH 8.0, 1% SDS, 1mM PMSF, 1µg/ml aproptinin, 1µg/ml leupeptin) and 
incubated for 10 min on ice. 200µl of the nucleic lysate was transferred into a 0.5ml 
thin wall tube. The lysate was sonicated (peak incidence power 140W, duty factor 
5.0%, 200Hz and 900seconds) to achieve an average length of the chromatin of about 
400bp. After sonication, the lysate nucleic lysate was cleared by centrifugation at 4°C 
for 10 min with 13,000 rpm. The supernatant was transferred into a fresh reaction tube 
and diluted 5 fold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2mM 
EDTA pH 8.1, 16.7mM Tris-Cl pH 8.0, 167mM NaCl, 1mM PMSF, 1µg/ml 
aproptinin, 1µg/ml leupeptin). The samples were pre-cleared with a mixture of 
sonicated salmon sperm DNA, BSA and protein A agarose for 30 min at 4°C with 
end-over-end rotation. The protein A agarose was pelleted at 4°C for 5 minutes with 
7,200 rpm and the supernatant was transferred to a fresh reaction tube. 10% of the 
supernatant were saved for the input control. The remaining lysate was divided into 
two parts. To one part, IgG was added to control for the antibody specificity. To the 
second part, the anti-p53 antibody CM5 was added. The samples were incubated at 
4°C overnight with end-over-end rotation. The next morning, 30µl of a 1:1 slurry of 
sonicated salmon sperm DNA, protein A agarose and BSA in TBS (50mM Tris-Cl 
pH7.5, 150mM NaCl) were added and incubated for 1 h at 4°C with agitation. The 
precipitates were pelleted by centrifugation at 4°C for 3 min with 7200 rpm and 
consecutively washed once with low salt wash buffer (0.1% SDS, 1% Triton X-100, 
2mM EDTA pH 8.1, 20mM Tris-Cl, pH 8.0), twice with high salt wash buffer (0.1% 
SDS, 1% Triton X 100, 2mM EDTA, pH 8.1, 20mM Tris-Cl, pH 8.0, 500mM NaCl), 
once with LiCl wash buffer (10mM Tris-Cl pH 8.0, 250mM LiCl, 1% NP40, 1% 
deoxycholic acid, 1mM EDTA pH 8.1) and twice with TE buffer (10mM Tris pH 8.0, 
1mM EDTA pH 8.1). The samples were briefly centrifuged at 4°C for 3 minutes with 
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7,200 rpm, any traces of buffer were removed and the antibody/protein/DNA 
complexes were eluted twice with 150µl freshly prepared IP elution buffer (100mM 
NaHCO3, 1% SDS) for 15 minutes on a mixer at maximal speed. The supernatants 
from both elutions were combined and the sample was centrifuged at room 
temperature for 3 minutes with 13,200 rpm to remove any traces of the protein A 
agarose. The supernatant was transferred to a fresh reaction tube.  
The crosslinks were removed from the sample by incubation with RNase A at 65°C 
overnight in the presence of 0.3M NaCl (f.c.). 2½ volumes ethanol were added and 
the DNA was precipitated at -80°C for 1 hour and collected by centrifugation at 4°C 
for 20 minutes with 14,000 rpm. The supernatant was aspirated, the pellet was 
air-dried and suspended in 10mM EDTA pH 8.1, 40mM Tris-Cl pH 6.5. 150µg/ml 
proteinase K were added and the sample was incubated for 2 h at 45°C to digest any 
remaining protein. 175µl TE buffer (10mM Tris-Cl pH7.5, 1mM EDTA) were added 
and the sample was extracted once with 300µl phenol/chloroform/isoamyl alcohol and 
twice with 300µl chloroform/isoamyl alcohol. 30µl of 5M NaCl, 5µg tRNA and 5µg 
Roti-Pink and 800µl ethanol were added and the DNA was precipitated at -20°C 
overnight. The DNA was collected by centrifugation at 4°C for 20 minutes with 
14,000 rpm and air-dried. The DNA pellet was dissolved in 50µl ddH2O and analyzed 
by PCR. 
2.2.11.2 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) was applied to amplify DNA fragments. This 
technique makes use of the principle that primers that are associated with a DNA 
fragment can be extended by the DNA polymerase Repeats of a denaturing, annealing 
and extension step allow the amplification of a DNA fragment from one copy to 
billion copies.  
For the PCR reaction, a template, in this case DNA purified from ChIP was mixed 
with 1µl of a forward and a reverse primer (each 50µg/µl), 0.5µl dNTPs (10mM), 
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GoTaq polymerase (Promega) and 2µl 10×GoTaq polymerase buffer and adjusted to 
20µl with ddH2O. The DNA was first denatured at 95
o
C for 2 minutes, followed by 
several cycles of a denaturing step (95
o
C, 30 sec), an annealing step (55
o
C, 20 sec), 
and an extension step (72
o
C, 30 sec). The number of cycles depends on the abundance 
of the template. After the polymerization reaction, the PCR product was analyzed by 
Agarose gel electrophoresis.  
2.2.11.3 Agarose gel electrophoresis 
1g agarose was boiled in 100ml 1×TAE buffer (40mM Tris pH 7.2, 20mM NaAc, 
1mM EDTA) until the agarose was completely dissolved. Ethidium bromide was 
added to a final concentration of 0.1µg/ml when the agarose solution was a bit cooled 
down. The solution was poured into a horizontal gel base. A comb was inserted into 
the agarose solution in order to produce wells where the DNA samples could be 
loaded. After solidification, the gel was inserted into a horizontal electrophoresis 
chamber and the chamber was filled with 1×TAE buffer until the whole gel was 
immersed in the buffer. The PCR products were mixed with 6×loading dye and 
carefully pipetted into the wells. A 2-log DNA-ladder was also applied next to the 
samples to allow an estimation of the size of the DNA fragment. Electrophoresis was 
performed at 160V until the colored front reached the middle or 2/3 of the gel. The 
DNA fragments were visualized under UV light and photographed.  
 
2.2.12 Extraction of RNA from eukaryotic cells and quantitative 
PCR (qPCR) 
Total RNA was purified by using the RNeasy Kit (Qiagen) according to the 
manufacturer’s instruction: Cells were washed twice with ice-cold PBS, scraped into 
PBS and collected by centrifugation at 4°C for 10 seconds with 13,300 rpm. The cell 
pellet was lysed in 600µl RLT buffer supplemented with 143mM β-mercaptoethanol. 
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The lysate was homogenized by passing it through a 20G needle fitted to a syringe. 
After homogenization, the lysate was mixed with the same volume of 70% ethanol 
and transferred onto an RNeasy spin column. The column was centrifuged with 
10,000 rpm for 15 sec at RT. The flow-through was removed and the column was 
successively washed once with 700µl RW1 buffer and twice with 500µl RPE buffer. 
The flow-through was discarded and the column was centrifuged for an additional 
minute to remove residual wash buffer. The RNA was eluted with 40µl RNase-free 
ddH2O and collected by centrifugation with 10,000 rpm for one minute. The 
concentration of the RNA was determined with a NanoDrop spectrophotometer.  
The optical density (OD) of the nucleic acid solution was measured at 260nm, 280nm 
and 230nm respectively. A unit of OD260 corresponds to 40µg/ml of single-stranded 
RNA calculated by the Beer-Lambert equation. The ratio of OD260/OD280 was used to 
estimate the purity of RNA. A value of 2.0 indicates an RNA solution that is free of 
protein, phenol and other contaminants.  
For cDNA synthesis, 1µg RNA was adjusted to 7µl with nuclease free water. 1µl 
rRNasin (20-40u/µl), 1 µl 10×DNase I buffer and 1µl DNase I were added and the 
sample was incubated for 30 minutes at 37
o
C to remove genomic DNA. The activity 
of DNase I was stopped by adding 1µl of a DNase stop solution followed by 
incubation at 65
o
C for 15 minutes. For first strand synthesis, 1µl of random primers 
(200ng/µl) were added and incubated at 70
o
C for 5 minutes. A mixture of 0.5µl of 
dNTPs (10mM each), 1µl of M-MLV RT (200u/µl), 4µl of M-MLV RT buffer and 
4.5µl of nuclease free water were then added and the reaction was incubated 
successively at 37
o
C for 10 minutes, 42
o
C for 40 minutes, and 70
o
C for 10 minutes. 
After reverse transcription, the cDNA was diluted in 100µl nuclease free water and 
kept in -20
o
C. For control, RNA was treated identically yet the reverse transcriptase 
was omitted from the reaction.  
To control the quality of the reverse transcription, a PCR was performed with primers 
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for the house-keeping gene RiBPO (See section 2.2.12.6) and analyzed by agarose-gel 
electrophoresis (See section 2.2.12.7). 
qRT-PCR was performed to determine the relative amount of different RNAs. 2µl of 
the cDNA were mixed with 10µl 2×SYBER GREEN Real-time Master Mix, 1 µl each 
of a gene-specific forward and reverse primer (50 ng/µl), and 4 µl nuclease free water 
and processed and analyzed by the ABI StepOnePlus System. The program was set 
according to the scheme shown in Figure 2.5. 
 
Figure 2.5 | Scheme of the qRT-PCR cycling procedure. The reaction starts with heating the 
samples for 15 min to 95
o
C followed by 40 cycles or denaturation, annealing and extention (95
o
C 
for 15 sec for denaturing and 60
o
C for 30 sec for annealing and extension). The third step is the 
melt curve and holding stage.  
All PCR reactions were performed in duplicates and with a control where no template 
has been added. A PCR reaction with primers for RiBPO was performed for internal 
control. A threshold was set to subtract the background. When the fluorescence 
intensity reached the threshold, the level of transcripts was recorded as the cycle 
threshold (CT). The relative amount of each gene was calculated by the ΔΔCT method: 
ΔCT (treated group) = CT (treated group target) - CT (treated group reference 
(RiBPO)) 
ΔCT (control) = CT (control target) - CT (control reference (RiBPO)) 
Then, the ΔΔCT between control and the sample was calculated: 
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  ΔΔCT = ΔCT (control) -ΔCT (treated group) 
Finally, the normalized ratio of the expression of a target gene was determined by the 
formula: 2
-ΔΔCT 
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3 RESULTS 
3.1 p53 is localized in the nucleus in mouse embryonic stem 
cells. 
The p53 protein is one of most well-known tumor suppressor protein and plays a 
crucial functions in somatic cells including induction of cell cycle arrest or apoptosis 
in response to DNA damage (Riley et al., 2008). However, despite of its 
anti-proliferative effect, p53 is reported to be highly expressed in mouse embryonic 
stem cells (mESCs) (Sabapathy et al., 1997; Solozobova and Blattner, 2010), a cell 
type that proliferates faster than somatic cells because of a shortened G1 phase 
(Becker et al., 2006). Before I started my investigations, I set out to confirm the 
previous observations that stem cells proliferate faster than somatic cells and that p53 
is present in a higher amount in mESCs than in differentiated cells. I lysed mESCs 
and mESCs that had been differentiated by incubation with retinoic acid for seven 
days and monitored abundance of p53 by Western blotting. For control, I also 
employed murine embryonic fibroblasts. To control for the specificity of the p53 
antibody, I included p53
-/-
 counterparts of the above mentioned cell types.  
As shown in figure 3.1A, the p53 protein was highly abundant in ESCs, and its 
abundance was strongly decreased in differentiated mESCs. In mouse embryonic 
fibroblasts (MEFs), p53 was even undetectable under these conditions. Hybridization 
with an antibody targeted against the stem cell marker Oct3/4 shows that the stemness 
character was present in mESCs and strongly decreased after incubation with retinoic 
acid to a level that was comparable to the MEFs (Figure 3.1A). 
In order to investigate whether mESCs proliferate at a higher rate than somatic cells, I 
plated 5×10
4
 mESCs per well into a 6-well plate, and to some of the cells, I added 
1μM (f.c.) retinoic acid at the time of plating to induce differentiation. For control, I 
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employed MEFs. Three days after plating, I determined the cell number.  
Figure 3.1 | p53 is highly expressed in mouse embryonic stem cells. A. murine embryonic 
fibroblasts (ESCs), mESCs that had been differentiated with 1μM retinoic acid for seven days 
(ESCs diff.), mouse embryonic fibroblasts (MEF) and their p53-deficient counterparts were lysed 
and the cell lysate was separated by SDS PAGE. The separated proteins were transferred onto a 
PVDF membrane. The membrane was blocked with 5% skimmed milk/PBST for 1 hour, 
incubated with the anti-p53 antibody 1C12 at 4
o
C overnight, washed 3 times with PBST and 
incubated with an HRP-coupled anti mouse antibody for 1 hour at room temperature. The 
membrane was washed twice with TBST and once with TBS. A mixture of an equal volumes of 
ECL solution I and II was distributed evenly over the membrane, and incubated for 1 minute. The 
membrane was wrapped in cling film and exposed against an X-ray film (GE Healthcare). 
Subsequent hybridizations with antibodies targeted against Oct3/4 to control for stemness; and 
against β-actin, for loading control, and p53 were performed as described for p53. B. mESCs and 
MEFs were plated at a density of 5×10
4
 cells/well in a 6-well plate. 1μM Retinoic acid (f.c.) was 
added to one well of mESCs (mESCs diff.) at the time of plating. Cells were counted three days 
after plating. The graph shows mean values and standard deviations of three independent 
experiments. 
As shown in figure 3.1B, the number of ESCs was almost three times higher than that 
of those ESCs that had been induced to differentiate (ESCs diff.) or of MEFs (Figure 
3.1B). Thus, mESCs proliferate significantly faster than differentiated cells despite the 
high amount of p53. 
As p53 is highly abundant in mESCs but the cells proliferate much faster than MEFs, 
for example, which have low amounts of p53 (Figure 3.1A), this raised the issue how 
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stem cells can proliferate fast regardless of the presence of a high amount of the p53 
proteins, that is highly anti-proliferative, at least in differentiated cells (Baker et al., 
1990; Diller et al., 1990; Mercer et al., 1990). Previous publications argued that 
mESCs can proliferate fast because of a cytoplasmic localization of p53 in stem cells 
(Aladjem et al., 1998; Han et al., 2008; Solozobova et al., 2009) that would interfere 
with its activities as a transcription factor. Since the localization of p53 might be 
crucial for its activity, I investigated whether p53 is indeed sequestered in the 
cytoplasm in mESCs.  
I first performed immunofluorescence staining for p53 of mESCs. I plated mESCs on 
feeder cells on and cultured them for two days. To control for the specificity of the 
antibodies, I also plated p53-deficient mESCs. I then fixed the cells, washed them 
with PBS and blocked them with 1% bovine serum albumin and 1% goat serum in 
PBS prior to the incubation with several different anti-p53 antibodies. Among the 
antibodies that I used was the anti-p53 antibody Pab421 that was used in previous 
investigations (Aladjem et al., 1998; Solozobova et al., 2009). To control for stemness, 
I also included an antibody against Nanog (Mitsui et al., 2003). For some slides, I 
omitted the first antibody, to control for the specificity of the secondary antibody. The 
next day, I washed the cover slips with PBS and incubated them with antibodies 
directed against mouse or rabbit IgG coupled to a fluorescent dye together with Draq5. 
After incubation, I washed the cover slips, mounted them onto microscope slides and 
analyzed them with a confocal microscope. In agreement with previous studies 
(Aladjem et al., 1998; Solozobova et al., 2009), I observed a signal in the cytoplasmic 
compartment in wild type mESCs when I applied the anti-p53 antibody Pab421 
(Figure 3.2). However, I also observed a signal of similar intensity in the cytoplasm of 
p53
-/-
 mESCs which are devoid of the p53 protein. Obviously the antibody Pab421 
recognizes a protein in mESCs that is not p53. In contrast, when I used the CM5 or 
the 1C12 anti-p53 antibody, I observed the majority of staining in the nuclear 
compartment of the stem cells. Moreover, I did not observe any staining in p53
-/-
 
mESCs when I employed the anti-p53 antibody 1C12, and only a weak staining when 
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I used the antibody CM5 (Figure 3.2). This result indicates that p53 may be localized 
in the nucleus in stem cells. Thus, the cytoplasmic appearance that was seen when the 
antibody Pab421 was used could eventually be an antibody-artifact.  
 
Figure 3.2 | p53 is localized in the nucleus in mouse embryonic stem cells. mESCs (p53
+/+
) and 
their p53-deficient derivative (p53
-/-
) were grown on feeder cells on coverslips, fixed with ice-cold 
acetone/methanol, blocked with 1% bovine serum albumin and 1% goat serum in PBS and 
incubated with the indicated antibodies diluted in 1% bovine serum albumin and 1% goat serum in 
PBS (Pab421: 1:200; 1C12: 1:2000; CM5: 1:1000; Nanog: 1:500; IgG: 1:1000. After primary 
antibody incubation and washing, the cells were incubated for 30 minutes in the dark with 
antibodies directed against mouse or rabbit IgG coupled with Alexa-Fluro-488, diluted 1:1,000 
(shown in green) together with Draq5 diluted 1:3,000 (shown in blue). Images were analysed on a 
Leica LSM microscope.  
To confirm the result from the immunofluorescence analysis, I fractionated mESCs 
into cytoplasmic and nuclear lysate and determined the amount of p53 in the two 
fractions. Apart from wild-type and p53
-/-
 mESCs, I also included mESCs that had 
been treated with retinoic acid to induce differentiation. To fractionate the cells, I 
suspended the cell pellet in a low salt homogenization buffer, after I had collected 
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them by centrifugation, incubated the samples shortly on ice to disrupt the cellular 
membrane and pelleted the nuclei by centrifugation. The supernatant after this 
centrifugation represented the cytoplasmic fraction. I purified the nuclei further by 
centrifugation through a sucrose cushion and disrupted them by applying a high salt 
lysis buffer. I then analyzed both fractions by SDS PAGE and western blotting. To 
compare the different anti-p53 antibodies, I had prepared four identical membranes 
onto which I had loaded an equal number of cells of the different cell types. Then I 
hybridized each of the membranes with a different anti-p53 antibody (Pab421, Pab246, 
CM5, 1C12). To control the purity of each fraction, I also monitored the GAPDH 
protein that is merely expressed in the cytoplasm and the Histone H3 protein that is 
merely expressed in the nucleus.  
 
Figure 3.3 | The majority of p53 is nuclear in mESCs. p53
+/+
 mESCs (D3), p53
-/-
 mESCs, and 
p53
+/+
 mESCs that had been differentiated by incubation with RA (D3 diff.) were harvested, 
washed with ice-cold PBS, scraped from the culture dish and collected by centrifugation The 
supernatant was aspirated and the cell pellet was suspended in four packed cell volumes 
homogenization buffer, incubated on ice for 5 minutes and collected by centrifugation. The 
supernatant that contained the cytoplasmic fraction was transferred into a new reaction tube. The 
nuclei were washed twice with ice-cold PBS, suspended in the same volume of lysis buffer that 
was used to release the nuclear fraction and disrupted by sonication. Lysates corresponding to 
equal amounts of cells were analysed by SDS PAGE and western blotting. Four identical 
membranes were prepared and each was incubated with a different anti-p53 antibody (1C12, CM5, 
Pab246, Pab421) as described in the legend to figure 3.1. Hybridization with GAPDH and Histone 
H3 was employed to monitor the efficiency of fractionation. 
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In consistency with the result from the immunofluorescence analysis, the anti-p53 
antibody Pab421 showed a strong signal in the cytoplasmic fractions from p53 
positive stem cells and differentiated cells (Figure 3.3). However, there was an even 
stronger signal also present in p53 negative cells. This was also the case for the 
Pab246 antibody that was used in a previous report (Han et al., 2008). The antibodies 
1C12 and CM5 gave a clear signal at approximately 53 kDa that was only detectable 
in p53 positive cells. The majority of this signal was in the nuclear fraction (Figure 
3.3), confirming the result obtained from immunofluorescence analysis. However, I 
also observed that some p53 protein was present in the cytoplasmic fraction, 
indicating that the p53 protein is present both in the nuclear and in the cytoplasmic 
compartment in stem cells (Figure 3.3). In differentiated cells, I could detect p53 only 
in the nuclear fraction. This was probably due to the low amount of p53 in this cell 
type and the poor sensitivity of this assay. 
In order to obtain further evidence that p53 is nuclear in stem cells, I treated cells with 
the CRM1 inhibitor Leptomycin B (LMB). LMB inhibits the shuttling of Mdm2 
between cytoplasm and nucleus resulting in increased p53 abundance in the nucleus 
of differentiated cells (Roth et al., 1998). Thus, if the p53 protein would be purely 
localized in the cytoplasm in stem cells, p53 should not accumulate in the nucleus 
after addition of LMB. To test this prediction, I first starved the cells for 16 hours by 
incubating the cells in culture medium without fetal bovine serum. I then changed the 
medium and incubated the cells overnight in complete cell culture medium and 20nM 
LMB. The next morning, I harvested the cells. I took an aliquot of the cells to analyze 
abundance of p53 in the whole cell lysate and fractionated the remaining cells into 
cytoplasmic and nuclear lysate. I then performed SDS PAGE and western blotting for 
further analysis. I prepared two identical membranes and hybridized these membranes 
with the anti-p53 antibodies 1C12 or CM5.  
In figure 3.4 it is shown that the p53 protein accumulated dramatically in the nucleus 
of mESCs (Figure 3.4).  In addition, p53 accumulated in the cytoplasm of stem cells 
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(Figure 3.4). This was not the case for e.g. PARC or Nanog, which were used to 
monitor stemness and efficient fractionation of the cells (Figure 3.4). 
Figure 3.4 | The p53 protein accumulates in stem cells after inhibition of nuclear export by 
Leptomycin B. mESCs were starved with serum free medium for 16 hours, then the medium was 
changed and the cells were cultured overnight in complete GlutaMAX DMEM containing 20nM 
LMB. The cells were harvested and an aliquot of the cells was reserved for whole cell lysate while 
the rest of the cells were separated into a cytoplasmic and nuclear fraction. Therefore, the cells 
were pelleted at 4
o
C for 5 minutes with 1,200 rpm. The cell pellet was suspended in 
homogenization buffer and incubated on ice for 5 minutes. The nuclei were released by 15 strokes 
with a homogenizer and collected by centrifugation. The supernatant contained the cytoplasmic 
fraction. The nuclei were purified by centrifugation through a sucrose cushion and lysed. The 
protein concentration of all the samples was determined and 50 µg of the cellular lysates were 
analyzed by SDS PAGE and western blotting as described in the legend to figure 3.1. p53 was 
detected by hybridization with the anti-p53 antibody 1C12 (diluted 1:10,000) and CM5 (diluted 
1:2,000). Hybridization of the membranes with PARC was used to monitor fractionation. 
Hybridization with Nanog was performed to control for the pluripotency of the stem cells. 
Membranes were stained with ink to control for equal loading of the membranes. Cyt, cytoplasm; 
WCL, whole cell lysate. 
 
3.2 The Anti-proliferative activity of p53 is compromised in 
mESCs. 
Since a majority of p53 is obviously nuclear also in stem cells, a different localization 
of p53 in stem cells and differentiated cells cannot account for the high proliferation 
rate of stem cells in the presence of these high amounts of p53. However, if p53 
RESULTS 
64 
 
would be inhibited in other ways, this could explain the high proliferation rate of 
mESCs. In order to test whether p53 is active in stem cells, I made use of the 
observation that cells that possess wild type p53 usually proliferate faster than their 
p53-negative counterpart (see e.g. (Li et al., 2012). If I would not see such a reduction 
in stem cells, this would be a good indication, that at least the anti-proliferative 
activity of p53 would be compromised in stem cells. I therefore monitored the 
proliferation of p53-positive mESCs and their p53-negative counterpart. I plated the 
stem cells on feeder cells and counted the cells every day. For control I plated feeder 
cells alone. To control for the authenticity of the result, I also monitored the 
proliferation of p53-positive and p53-negative MEFs, and of stem cells that were 
induced to differentiate by adding all-trans-retinoic acid.  
As shown in Figure 3.5A, p53 positive stem cells proliferated as fast as p53 negative 
cells (Figure 3.5A). In contrast to the mESCs and in consistency with the reported 
work (Li et al., 2012), p53-positive MEFs proliferated much slower than the 
p53-negative MEFs (Figure 3.5A). Also, p53-positive differentiated cells proliferated 
slower than their p53
-/-
 counterpart (Figure 3.5A). These results suggest that the 
variation in the proliferation rate in the presence and absence of p53 is an attribute of 
differentiated cells but not of stem cells. 
To confirm the result that the proliferation of stem cells is not affected by the 
presence of p53, I performed an MTT assay. The MTT assay is a colorimetric assay 
that measures the reduction of 3-(4, 5-dimethythialzol-2-yl)-2, 5-diphenyl tetrazolium 
bromide (MTT) into the insoluble formazan salt by the mitochondrial succinate 
dehydrogenase. As this reduction of MTT is accompanied by a change in the color, 
the conversion can be monitored spectrophotometrically. Since reduction of MTT 
only occurs in metabolically active and thus in living cells, it can be used to determine 
the relative amount of living cells (Heeg et al., 1985). 
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Figure 3.5 | The anti-proliferative activity of p53 is compromised in mESCs. A. Wild-type 
mESCs (p53
+/+
), their p53-deficient derivative (p53
-/-
), mouse embryonic fibroblasts (p53
+/+
 MEF) 
and their p53-deficient counterpart (p53
-/-
 MEF) were plated at a density of 5×10
4
 cells/well in a 
6-well plate. Differentiated mESCs (mESCs diff.), and the corresponding p53
-/-
 cells were plated 
at a density of 1×10
5
 cells/well. At the time of plating, 1μM (f.c.) retinoic acid was added to 
differentiate the cells. All cells were counted each day for three days. The graph shows mean 
values and standard deviations of three independent experiments. B. p53
+/+
 mESCs and their 
corresponding p53
-/-
 derivative (p53
-/-
 mESCs) were plated at a density of 5×10
4
 cells/well in a 
6-well plate on
 
feeder cells. p53
+/+
 MEFs and their p53-deficient counterpart (p53
-/-
 MEFs) were 
plated at a density of 5×10
4
 cells/well in a 6-well plate. At one, two and three days after plating, 
the medium was aspirated and 125μl MTT solution (5mg/ml) and 250μl complete growth medium 
were added and the cells were incubated for 4 hrs at 37°C and 6% CO2. Then the medium was 
aspirated and 125ul isopropanol were added to each well and vortexed to release the formazan. 
100μl of the formazan solution were diluted 1:10 with isopropanol and 150ul of this solution were 
transferred into a 96-well plate. The absorbance was determined at 595 nm. The graph shows 
mean values and standard deviations of three independent experiments. 
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For the MTT assay, I seeded 5x10
4
 p53-positive ESCs and their p53-negative 
counterpart (p53
-/-
) per well in a 6-well plate and determined the MTT conversion 
each day. To control the authenticity of this assay, I also measured the MTT 
conversion in p53-positive (p53
+/+
 MEF) and p53-negative MEF (p53
-/-
 MEF). 
In figure 3.5 B, it is shown that the conversion of MTT is a bit lower in p53
+/+
 stem 
cells than in p53
-/-
 stem cells (Figure 3.5B). However, the difference in the MTT 
conversion between p53
+/+
 stem cells and p53
-/-
 stem cells was much smaller than that 
of p53
+/+
 and p53
-/-
 MEFs (Figure 3.5B). Thus this experiment confirms the result 
from counting the cells that the effect of p53 on the proliferation of stem cells is 
insignificant, which is in contrast to the effect of p53 on the proliferation of 
differentiated cells.  
The above shown results indicate that the anti-proliferative activity of p53 is 
compromised in mESCs. However, these results could also be due to changes that 
may have occurred in the p53-negative mESCs in order to adapt to the absence of p53. 
To see whether the similar proliferation rate of p53-positive and p53-negative mESCs 
may indeed be caused by adaptive changes in p53
-/- 
stem cells or whether it really 
reflects a compromised function of p53 in mESCs, I downregulated p53 in mESCs 
and in mESCs that had been differentiated by incubation with retinoic acid. 
Seventy-two hours after siRNA transfection, I monitored cell proliferation by the 
MTT assay and downregulation of p53 by western blotting.  
As shown in figure 3.6A, differentiated cells clearly proliferated faster when p53 was 
downregulated. Such a difference in cell proliferation was, however, not seen when 
p53 was downregulated in mESCs (Figure 3.6A). Here, the cells proliferated even 
slightly slower, although the difference was not statistically significant. The Western 
blot shown in part B shows that p53 was downregulated to a similar extent in the stem 
cells and the differentiated cells (Figure 3.6B). 
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Figure 3.6 | Transient downregulation of p53 did not change the proliferation of mESCs. 
mESCs and mESCs that had been differentiated by incubation with retinoic acid for seven days 
(mESCs diff.) were transfected with a siRNA targeted against p53 or with a control siRNA in 
triplicates. A. Seventy-two hours after transfection, 125ul MTT solution (5mg/ml) and 250μl 
DMEM were added to two wells of the triplicate and the cells were incubated for 4 hrs. Then the 
medium was aspirated and 125μl isopropanol were added to each well and vortexed thoroughly to 
release the formazan. 100μl of the dissolved formazan solution were diluted 1:10 with isopropanol 
and 150μl of this solution were transferred into a 96-well plate. The absorbance of the diluted 
formazan solution was measured at 595 nm. The graph shows mean values and error bars of two 
(mESCs diff.) or three (mESCs) independent experiments. B. The third sample of the triplicate 
was lysed in NP40 lysis. 30 µg of the lysate were separated by an SDS-PAGE gel and further 
analyzed by western blotting. p53 was detected by hybridizing the membrane with the 1C12 
anti-p53 antibody as described in the legend to figure 3.1. Hybridization with β-Actin was 
performed for loading control 
Finally, I treated the cells with Nutlin in order to see whether p53 is active in stem 
cells. Nutlin is a cis-imidazoline analogy that binds to the p53-binding pocket of 
Mdm2 and inhibits the interaction between MDM2 and p53. In the presence of Nutlin, 
p53 is released from Mdm2-mediated control which leads to the stabilization and 
activation of p53 (Vassilev et al., 2004) independent of post-translational 
modifications that occur e.g. in response to DNA damage. If p53 is active in mESCs, 
the administration of Nutlin should strongly reduce the proliferation of mESCs as it 
does in more differentiated cells (Zauli et al., 2007).  
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To investigate whether p53 is active in mESCs, I incubated mESCs and mESCs that 
had been differentiated by incubation with retinoic acid for seven days with 5µM 
Nutlin. 72 hours after addition of Nutlin, I monitored the cell density by MTT assay. 
For control, I also measured the cell density by MTT assay in p53
-/-
 mESCs (p53
-/-
) 
and their differentiated derivatives (p53
-/-
 diff).  
 
Figure 3.7 | Induction of p53 by Nutlin had no effect on the proliferation of mESCs. A. 
mESCs, mESCs that had been differentiated with retinoic acid (mESCs diff.), and their 
p53-deficient counterparts (p53
-/-
 and p53
-/-
 diff) were plated in quadruplicates and treated with 5 
µM Nutlin or with DMSO for control. Seventy-two hours after plating, relative cell proliferation 
was assessed from triplicates by MTT assay as described in the legend to figure 3.6A. The graph 
shows mean values and error bars of two independent experiments. Relative cell numbers of mock 
treated cells were set to 100%. B. The remaining part of the quadruple was lysed thirty-two hours 
after Nutlin treatment and abundance of p53 was assessed by Western blotting as described in the 
legend to figure 3.1 using the 1C12 anti-p53 antibody diluted 1:10,000. Hybridization with 
β-Actin (diluted 1:1,000) was performed for loading control. 
As shown in figure 3.7A, the treatment of differentiated cells with Nutlin obviously 
reduced cell proliferation (mESCs diff.) when p53 was present, which is consistent 
with the report by Zauli and colleagues (Zauli et al., 2007). In contrast, the treatment 
of mESCs with Nutlin did not reduce their proliferation (Figure 3.7A). Part B of the 
figure shows that treatment of the cells increased p53 abundance both in stem cells 
and in differentiated cells (Figure 3.7B).  
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All these results support the concept that the anti-proliferative activity of p53 is 
compromised in mESCs.  
 
3.3 p53 is modified at lysine 379, serine 15 and serine 392 in 
response to DNA damage in mESCs, but not under normal 
culture condition. 
Since I found that the anti-proliferative activity of p53 is compromised in mESCs, I 
wondered which mechanism could impede p53’s activity. As p53’s activity is tightly 
controlled in somatic cells by a variety of posttranslational modifications (PTM) 
(Bode and Dong, 2004; Boehme and Blattner, 2009; Dai and Gu, 2010), I wondered 
whether the impaired anti-proliferative activity of p53 in stem cells could also be due 
to PTMs and whether the PTMs of p53 are different in mESCs and differentiated cells. 
To investigate this possibility, I monitored p53’s PTM in mESCs and differentiated 
cells by using commercially available antibodies against p53 phosphorylated at serine 
6 (S6), at serine 15 (S15) and at serine 392 (S392) as well as against p53 acetylated at 
lysine 379 (K379). I investigated modifications at these sites since these PTMs were 
reported to be crucial for p53’s activity (Dumaz and Meek, 1999; Higashimoto et al., 
2000; Keller and Lu, 2002; Sagakuchi et al., 1998). I therefore plated mESCs and 
mESCs that had been differentiated for seven days with retinoic acid. For positive 
control, I subjected a part of the stem cells and differentiated cells to ionizing 
radiation since DNA damage has been shown to increase p53’s PTMs at these sites 
(Dumaz and Meek, 1999; Higashimoto et al., 2000; Keller and Lu, 2002; Sagakuchi et 
al., 1998). To control for the specificity of the antibodies, I included the p53-negative 
counterparts of the stem cells and differentiated cells. Two hours after irradiation, I 
lysed the cells and monitored p53 modifications as well as total levels of p53 by 
western blotting.  
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Figure 3.8 | p53 is modified at lysine 379, serine 15 and serine 392 in response to DNA 
damage. mESCs, mESCs that had been differentiated with retinoic acid for 7 days (Diff.) and 
their p53-negative counterparts were irradiated with 7 Gray or left unirradiated. Two hours after 
irradiation, cells were harvested and the cell number was determined. Then the cells were lysed at 
1million cells/100μl lysis buffer. Five identical membranes were prepared by separating 30μl of 
cell lysate per lane by SDS-PAGE and transferring the proteins onto a PVDF membrane. The 
membranes were hybridized as described in the legend to figure 3.1 with antibodies directed 
against phosphorylated p53 (S6, diluted 1:1,000), phosphorylated p53 (S15, diluted 1:3,000), 
phosphorylated 53 (S392, diluted 1:3,000), acetylated p53 (K379, diluted 1:3,000) or against 
pan-p53 (1C12, diluted 1:10,000). Hybridization with Nanog (diluted 1:2,000) was performed to 
control for stemness and with β-Actin (diluted 1:1,000) to allow for the comparison of the loading 
of the different membranes. Western Blots were developed by ECL. 
 
As shown in figure 3.8, p53 was acetylated at K379 and phosphorylated at S15 and 
S392 after DNA damage. However, apart from the anti-phosphorylated p53 antibody 
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at serine 392, which gave a very weak signal also for non-irradiated mESCs, none of 
the antibodies recognized p53 of undamaged cells, neither in stem cells nor in 
differentiated cells (Figure 3.8). None of these antibodies gave signals in p53 negative 
cells, proofing their specificity (Figure 3.8).  
 
3.4 A fraction of p53 with a neutral pI exists exclusively in mouse 
embryonic stem cells. 
All the antibodies against modified p53 that were used in figure 3.8 were raised 
against sites of p53 that are modified in response to DNA damage., However, as 
shown in figures 3.5 to 3.7, p53’s activity was compromised in ESCs under normal 
growth conditions. Thus, if the PTMs of p53 differ between stem cells and 
differentiated cells, these modifications may be different from those that are added to 
p53 after genotoxic stress. Valeriya Solozobova from our lab, had already observed 
that mESCs have a fraction of p53 with a neutral pI that is absent in p53 from  
 
Figure 3.9 | A fraction of p53 with a neutral pI exists exclusively in stem cells. Lysates of 
mESCs and mESCs that had been differentiated with retinoic acid for 7 days (mESCs Diff.) were 
separated by two-dimensional gel electrophoresis and blotted. Abundance of p53 was determined 
by incubation with the 1C12 antibody. Hybridization with an antibody targeted against PCNA 
(proliferating cell nuclear antigen) was performed for control. (Courtesy of Valeria Solozobova) 
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differentiated cells (see Figure 3.9). I thought that this difference could be important 
for stem cell function and therefore I elaborated further on this discovery. I was 
particularly interested whether this alteration is due to changes in the phosphorylation 
or acetylation of p53 since these modifications have a strong impact on p53 function 
(Boehme and Blattner, 2009). To find out whether p53 is acetylated in mESCs, I 
treated the cells with a combination of nicotinamide (NA) and trichostatin A (TSA) 
prior to harvesting the cells. Both compounds inhibit histone deacetylases, the major 
deacetylating enzymes in the cell (Bitterman et al., 2002; Yoshida et al., 1990). These 
inhibitors furthermore strongly enhance p53 acetylation in differentiated cells (Luo et 
al., 2001; Terui et al., 2003). In order to find out whether p53 is phosphorylated in 
mESCs, I treated the cell lysate with λ-phosphatase. I then separated the cell lysates 
by 2D-gel electrophoresis and monitored p53 abundance by western blotting. To 
control for the activity of λ-phosphatase, I irradiated mESCs and differentiated cells 
with ionising irradiation, which strongly increases p53 phosphorylation at serine 15 
(Dumaz et al., 1999; see also figure 3.10). I prepared cellular lysate from these cells 
and treated a part of the lysate under the same conditions that I used for treating the 
cell lysate that I then analysed by 2D-western blotting. 
As shown in figure 3.10A, treatment of the lysate of stem cells with λ-phosphatase 
shifted a fraction of p53 beyond a pI of 8.6. In samples that had not been treated with 
the phosphatase, there was much less p53 with a pI greater than 8.6 (Figure 3.10A). 
This result shows that p53 in stem cells is constitutively phosphorylated. For 
differentiated cells, I obtained a similar result. Here, the charge of p53 was also 
changed after phosphatase treatment. Here, a fraction of p53 appeared with a pI 
between 5.6 and 8.6 that is absent in the control cells. However, no p53 with a pI 
beyond 8.6 was detected in these samples. In fact, p53 from differentiated cells that 
had been treated with phosphatase resembled untreated p53 from stem cells (Figure 
3.10A). Part B of this figure shows a strong decrease in p53 phosphorylation when the 
samples had been treated with λ-phosphatase prior to gel electrophoresis 
demonstrating that the treatment with the phosphatase indeed removed phosphate 
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groups from p53 under the applied conditions A strong signal for the stem cell marker 
Oct3/4 shows that the mESCs that were used for this experiment had maintained their 
stem cell properties (Figure 3.10B). 
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Figure 3.10 | p53 is constitutively phosphorylated in mESCs. mESC and mESCs that had been 
differentiated with retinoic acid for 7 days (mESC Diff.) were harvested, suspended in 
phosphatase buffer and sonicated. Where indicated, cells were irradiated with 7.5 Gray and 
harvested 30 minutes after irradiation. Lambda phosphatase was added at a concentration of 200 
units per 100 µg of protein (or cells were left without phosphatase for control) and incubated for 
30 minutes at 30°C. The proteins were TCA-precipitated, the pellet was suspended in Urea Lysis 
buffer and the lysate was cleared by centrifugation. A. 1mg of the protein was diluted with an 
equal volume of 2×IEF buffer, loaded onto an 18 cm Immobiline DryStrip pH 3-11 NL and 
incubated until all the sample solution was sucked by the strip. Isoelectric focusing (IEF) was 
performed at 200V for 3.5 hours, at 500V for 3.5 hours, at 1000V for 3.5 hours, at a gradient up to 
8000V for 1 hour and at 8000V for 11 hours. After IEF, the gel was equilibrated and alkylated and 
layered on top of an SDS-PAGE gel. After electrophoresis, the proteins were transferred onto a 
PVDF membrane and detected by immunodetection as described in the legend to figure 3.1. B. 
50µg of protein were separated by SDS-PAGE and transferred onto a PVDF membrane. 
Determination of the amount of phosphorylated p53 (antibody diluted 1:1,000), total p53 (1C12 
diluted 1:10,000), Oct 3/4 (antibody diluted 1:2,000) to control for stemness, and β-Actin 
(antibody diluted, 1:1,000) for loading control, was performed as described in the legend to figure 
3.1. 
Treatment of mESCs with a combination of TSA and NA strongly increased the 
negative charge of p53 from stem cells resulting in the complete removal of the 
fraction of p53 with a neutral pI (Figure 3.11A). In differentiated cells, there was also 
a tendency to increase the fraction pf p53 with a pI between 4.6 and 5.2 (Figure 3.11). 
The effect was, however, not as obvious as in stem cells. Part B of this figure shows 
that the treatment with TSA and NA increased p53 acetylation under the applied 
conditions in stem cells and differentiated cells (Figure 3.11B). A strong signal for the 
stem cell marker Oct3/4 demonstrates the pluripotency of the mESCs that were used 
for this experiment (Figure 3.11B).  
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Figure 3.11 | p53 is constitutively deacetylated in stem cells. mESCs and mESCs that had been 
differentiated with retinoic acid for 7 days (mESCs Diff.) were treated with 1 µM trichostatin A 
and 5 mM nicotinamide for 6 hours. A. The cells were suspended in Urea Lysis buffer and 
processed as described in the legend to figure 3.10A. B. 50µg of proteins were separated by 
SDS-PAGE gels and transferred onto a PVDF membrane. Determination of phosphorylated p53 
(antibody diluted 1:1,000), total p53 (1C12, diluted 1:10,000), Oct 3/4 (antibody diluted 1:2,000) 
to control for stemness, and β-Actin (antibody diluted, 1:1,000) for loading control, was 
determined as described in the legend to figure 3.1. 
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3.5 p53 is present in a large protein complex in mESCs that 
contains the inhibitory protein MDMX.  
Another possibility to achieve inactivation of p53 is by its association with inhibitory 
proteins (Boehme and Blattner, 2009). In order to get an idea whether p53 is 
associated with different proteins in mESCs and differentiated cells, I performed 
sucrose gradient centrifugation and monitored p53’s abundance in the different 
fractions. Sucrose gradient centrifugation is a method by which proteins and protein 
complexes can be separated by their molecular weight under native conditions. After 
layering the protein lysate onto the sucrose gradient, the gradient is centrifuged. 
During this centrifugation step, proteins and protein complexes travel through the 
sucrose gradient until they arrive at the layer where the density of the sucrose gradient 
matches with their molecular weight. After this centrifugation step, fractions can be 
taken and analysed for the presence of the protein of interest. However, while this 
method is well appropriate to monitor changes in the size of proteins or protein 
complexes, it does not tell which proteins are in the complex unless further analytical 
tools such as western blotting are performed. To investigate whether p53 from mESCs 
and from differentiated cells may be in different protein complexes (and thus 
associated with different proteins), I used mESCs and differentiated cells, lysed the 
cells in a mild buffer to prevent the dissolution of the complexes and loaded the 
cleared cellular lysate onto a sucrose gradient. After centrifugation, I collected 
fourteen fractions and analysed these fractions by western blotting.  
Most interestingly, hardly any p53 protein existed as monomers or dimers both in 
stem cells and in differentiated cells. In fact, most p53 existed in protein complexes 
larger than 660 kDa. Thus, p53 is almost exclusively associated with other proteins 
and protein complexes. In contrast to my expectations, I could not see a difference in 
the distribution of p53 between mESCs and differentiated cells (Figure 3.12). Thus, 
there is no obvious difference in the size of the complexes which contain p53 in 
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mESCs and differentiated cells. This, however, does not rule out the possibility that 
there is a difference in individual proteins in these complexes. In differentiated cells, 
p53 activity is mainly inhibited by MDM2 and MDMX (Shvarts et al., 1996; Haupt et 
al., 1996). I therefore wondered whether there is a difference in the binding of MDM2 
or MDMX to p53 between mESCs and differentiated cells. I reasoned that if MDM2 
or MDMX are associated with p53 in stem cells or differentiated cells, then they 
should co-elute with p53 from sucrose gradients. I therefore analysed the fractions 
from the sucrose gradient also for the presence of MDM2 and MDMX.  
 
Figure 3.12 | The distribution of p53 after sucrose density centrifugation is not altered after 
differentiation. mESCs and mESCs that had been differentiated by incubation with retinoic acid 
for 7 days (mESCs diff.) were lysed in a mild lysis buffer and cleared by centrifugation. 2mg of 
the lysate were loaded onto a 10-40% sucrose gradient and centrifuged for 18 h. After 
centrifugation, fractions were collected and further analyzed by SDS PAGE and western blot. The 
abundance of p53 was detected by hybridization with the anti-p53 antibody 1C12 (diluted 1:0,000) 
as described in the legend to figure 3.1. Hybridization with α-7 (MCP72, diluted 1:2,000) was 
performed for internal control. 
As shown in figure 3.13, MDMX eluted in exactly the same fractions from the 
sucrose gradient as p53, indicating that these two proteins could associate with each 
other. This elution pattern was the same in stem cells and differentiated cells (Figure 
3.13). However the signal for MDMX was considerably weaker in differentiated cells 
(Figure 3.13). In contrast to MDMX, the majority of MDM2 is eluted in fractions that 
corresponded to a much smaller molecular weight than the fractions where p53 eluted. 
From the twenty-eight fractions that I obtained from a sucrose gradient, only six 
RESULTS 
78 
 
(fraction 12-18) contained larger amounts both of p53 and MDM2. Yet again, there 
was no discernible difference in the distribution of MDM2 along the sucrose gradient 
between mESCs and differentiated cells. Like it was the case for MDMX, the signal 
for MDM2 was weaker in differentiated cells (Figure 3.13), indicating that both 
inhibitory proteins MDM2 and MDMX are present in greater amounts in stem cells. 
The presence of a strong signal for the stem cell marker Oct3/4 in the mESCs lysate 
demonstrates the pluripotency of the mESCs that were used for this experiment 
(Figure 3.13). The presence of a signal for α7 in fractions 12-18 of the different 
gradients shows that the elution profile of the different gradients is comparable. 
(Figure 3.13). 
 
Figure 3.13 | MDMX co-elutes with p53 from sucrose gradients. mESCs and mESCs that have 
been differentiated by incubation with retinoic acid for seven days (mESCs diff.) were lysed in a 
mild lysis buffer and processed as described in the legend to figure 3.12. The abundance of p53 
was detected by hybridization with anti-p53 antibody 1C12 (diluted 1:0,000). Abundance of 
MDM2 (4B2, diluted 1:1,000), MDMX (diluted 1:3,000), Oct3/4 (diluted 1: 2,000) and of α-7 
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(MCP72, diluted 1:2,000), for internal control, was monitored by Western blotting. 
Since the results from the sucrose gradient centrifugation suggested that the amount of 
MDM2 and MDMX might be decreased during differentiation, I investigated the 
abundance of MDM2 and MDMX in stem cells and during differentiation in more 
detail. I plated mESCs, cultured them in complete DMEM medium supplemented 
with retinoic acid and harvested cells on day 0, 1, 3 and 5 after retinoic addition. I 
then monitored abundance of MDM2 and MDMX by western blotting. 
 
Figure 3.14 | Abundance of MDM2 and MDMX is decreased during differentiation of 
mESCs. mESCs were treated with retinoic acid for differentiation. At the indicated days after 
addition of retinoic acid, cells were collected and lysed. 30μg of the lysate were separated by 
SDS-PAGE and the proteins were transferred onto a PVDF membrane. Abundance of MDMX 
(antibody diluted 1:3,000), p53 (1C12, diluted 1:10,000) and MDM2 (4B2, diluted 1:1,000) was 
monitored by western blotting as described in the legend to figure 3.1. Abundance of Nanog (C4, 
diluted 1:2,000) was determined to control for stemness and of β-Actin (I-19, diluted 1:1,000) for 
loading control. 
As shown in figure 3.14, MDMX levels were very high in stem cells and decreased 
rapidly during differentiation. Already one day after the treatment of stem cells with 
retinoic acid, the signals for MDMX was strongly decreased, even stronger than that 
of the stem cell marker Nanog (Figure 3.14). Consistent with previous reports, p53 
levels were also decreased during differentiation (Sabapathy et al., 1997; Solozobova 
and Blattner, 2010). However, while the decrease in the abundance of p53 was slowed 
down, after an initial strong drop, which allowed a clear detection of p53 at day 3 
after the initiation of differentiation, abundance of MDMX was further strongly 
decreased and was basically undetectable three days after addition of retinoic acid 
(Figure 3.14). Abundance of MDM2 was also decreased during differentiation, but 
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this decrease was slower and weaker than that of p53 or MDMX (Figure 3.14).  
After having found that MDMX is highly abundant in stem cells and downregulated 
during differentiation, I wondered whether MDMX indeed regulates p53 activity in 
mESCs. To test this, I transfected mESCs with a siRNA targeted against MDMX. As 
the mdm2 gene is a transcriptional target of p53, I monitored abundance of the MDM2 
protein to examine p53 activity (Barak et al., 1993).  
 
Figure 3.15 | Downregulation of MDMX increases MDM2 protein levels in mESCs. mESCs 
were transfected with a siRNA that was directed against MDMX or with a control siRNA. 48h 
after transfection, cells were lysed. 30μg protein were separated by SDS PAGE and transferred 
onto a PVDF membrane. Abundance of MDM2 (4B2 diluted 1:1,000), p53 (1C12, 1:1,000) and 
MDMX (antibody diluted 1:3,000) was performed as described in the legend to figure 3.1. 
Hybridization with an antibody directed against β-Actin (I-19, diluted 1:1,000) was used to 
monitor equal loading of the gel. 
As shown in figure 3.15, downregulation of MDMX results in a strong increase in the 
amount of the MDM2 protein, while the amount of the p53 protein remained 
unchanged (Figure 3.15). This result suggests that MDMX controls p53 activity rather 
than p53 protein levels. The decrease in the signal for MDMX shows that the 
downregulation was successful. Similar intensity of the signals for β-Actin show that 
equal amounts of proteins were loaded onto the gel (Figure 3.16). 
Since MDMX expression was decreased during differentiation and MDMX 
expression seemed to be important for controlling p53 activity in stem cells, I 
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wondered that by which mechanism MDMX could be responsible for the high amount 
of MDMX in mESCs. In tumor cells, alternative splicing is an efficient mechanism to 
modulate MDMX protein levels (Lenos et al., 2012). In collaboration with 
Jean-Christoph Marine in Gent, Belgium, I investigated whether the splicing of 
MDMX may differ between stem cells and differentiated cells.  
 
  
Figure 3.16 | Inclusion of Mdm4 exon 7 is decreased upon differentiation of mEScs. mESCs 
were treated with retinoic acid (RA) for differentiation. At the indicated days, cells were harvested 
and divided into two aliquots. A. RNA was prepared from one of the aliquots and the abundance 
of the splice products MDMX-FL (full length) and MDMX-S (short form) was performed by PCR 
using isoform-specific primers. Gapdh levels served for loading control. B. The intensity of the 
bands for the FL- and S-forms was quantified and the ratio between the two bands was calculated. 
The ratio between MDMX-FL and MDMX-S of mESCs was set to 1. C. 30μg of lysate were 
separated by SDS PAGE and the proteins were transferred to a PVDF membrane. Abundance of 
MDMX (antibody diluted 1:3,000) was determined as described in the legend to figure 3.1. 
Hybridisation with an antibody directed against Oct3/4 (C10, diluted 1:2000) was performed to 
monitor differentiation and of β-Actin (I-19, diluted 1:1,000) for loading control. 
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Therefore, I induced differentiation in mESCs by incubating the cells with retinoic 
acid. At day 0, 1, 2 and 4 after addition of retinoic acid, I harvested the cells and 
divided each sample into two aliquots. One of the aliquots I used to monitor MDMX, 
and Oct3/4 levels as an indication for ongoing differentiation. The second aliquot, I 
sent to Jean-Christoph Marines’ lab where the RNA was isolated and MDMX splicing 
monitored.  
In agreement with the decrease of MDMX protein levels during differentiation, we 
observed that the amount of the full lengths MDMX RNA (MDMX-FL) was reduced 
(Figure 3.16A) while the amount of the shorter form of the MDMX RNA (MDMX-S) 
was increased (Figure 3.16A). Since rather the ratio between MDMX-S and 
MDMX-FL than the absolute abundance seems to be important for the abundance of 
the MDMX protein (Jean-Christoph Marine, personal communication), we calculated 
the ratio between MDMX-FL and MDMX-S. As shown in figure 3.16B, the ratio of 
MDMX-FL and MDMX-S parallels the decrease in MDMX protein levels in mESCs 
during differentiation (Figure 3.16B). Part C of the figure shows that Oct3/4 was 
highly abundant in mESCs. After initiation of differentiation, the intensity of the 
signal for Oct3/4 declined and was undetectable 4 days after differentiation (Figure 
3.16C). In consistency with the result shown in figure 3.14, the MDMX protein level 
also decreased during differentiation (Figure 3.16C).  
 
3.7 Splicing of p53 is altered during retinoic acid induced 
differentiation 
Another possibility for the loss of p53’s antiproliferative activity in stem cells could 
be alternative splicing of p53. For instance, overexpression of the p53-isoform 
Δ133p53α or loss of the expression of the p53-isoforms p53β and p53γ was found in 
breast cancer cells (Anensen et al., 2006; Bourdon et al., 2005; Bourdon et al., 2011). 
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As I already observed changes in the splicing of MDMX during differentiation, I 
considered it very likely that p53 may also be alternatively spliced during 
differentiation. 
In order to investigate this possibility in more detail, I induced differentiation of stem 
cells by retinoic acid and harvested the cells at 0, 2, 4 and 6 days after induction of 
differentiation. To control for the p53-specificity of the antibodies, I also employed 
p53-negative stem cells that I also induced to differentiate. I lysed the cells and 
determined the abundance of different p53 isoforms by hybridizing the membrane 
with the isoform-specific antibody SAPU that was provided to me by Jean-Christoph 
Bourdon, Dundee, Scotland.  
 
Figure 3.17 | Abundance of p53 isoforms is altered after retinoic acid induced differentiation 
of mESCs. mESCs were treated with retinoic acid (RA) for differentiation. At the indicated days, 
cells were harvested and divided into two aliquots. A. 30μg of the lysate of one of the aliquots 
were mixed with the 4×stock solution NuPAGE
®
 LDS Sample Buffer, loaded onto a NuPAGE
® 
10% 
Bis-Tris polyacrylamide gel and separated in 1×NuPAGE
®
 MOPS SDS Running buffer 
supplemented with 0.2% Antioxidants. The proteins were transferred onto a PVDF membrane and 
abundance of p53 was detected by hybridization with the anti-p53 antibody SAPU (diluted 
1:2,000) as described in the legend to figure 3.1. Hybridisation with an antibody directed against 
tubulin (diluted 1:3,000) was used for loading control.Arrows point to bands that are absent in 
p53-negative cells and whose intensity is changed during differentiation. B. The second aliquot 
was lysed in NP40 lysis buffer. 30μg of the lysate were separated by SDS-PAGE and transferred 
onto a PVDF membrane. Abundance of p53 was detected by hybridization with the anti-p53 
antibody 1C12 (diluted 1:10,000) as described in the legend to figure 3.1. Abundance of Oct3/4 
(C10, diluted 1:2000) was determined to control for stemness and hybridisation with an antibody 
directed against tubulin (diluted 1:3,000) was used for loading control. 
When the membranes where hybridized with the anti-p53 antibody SAPU, the p53 
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signal at around 53kDa was decreased with ongoing differentiation (purple arrow, 
Figure 3.17A). Concomitantly, a signal around 48kDa and a faint signal of a slightly 
smaller size were increased, which most likely represent the Δ40p53 and the 
Δ40p53AS isoforms (blue arrow, Figure 3.17A). In addition, two other signals were 
increased after retinoic acid induced differentiation, one at around 40kDa (red arrow) 
and the other one at around 18kDa (bright yellow arrow; Figure 3.19A). Since no 
isoforms of this size have been described as yet, these bands may represent novel and 
eventually stem cell-specific isoforms of p53. Most importantly, none of these signals 
come up in p53-negative stem cells, demonstrating the specificity of the SAPU 
antibody. Part B shows the abundance of total p53. The decrease in the signal for 
Oct3/4 reflects ongoing differentiation after addition of retinoic acid to the stem cells. 
 
3.8 Wild-type p53 controls a similar set of target genes in 
stem cells as mutant p53 in differentiated cells. 
As described above, the anti-proliferative activity was compromised in mESCs 
(Figure 3.5). Since there is a high amount of p53 present in stem cells, I wondered 
whether p53 might have other functions in stem cells than inhibiting proliferation. 
Such a function could be quite different from its functions in differentiated cells. To 
address this question, I performed an RNA-sequencing experiment. I extracted RNA 
from wild-type mESCs and from mESCs with a homozygous deletion of the p53 gene 
and handed the RNA over to our sequencing department where the RNA first 
underwent a quality control test. The RNA samples showed no sign of degradation 
with more than 89% of the fragments passing the illumine chastity filter. (Table 3.1).  
 
Table 3.1 | Quality of the RNA. RNA was prepared from mESCs with wild-type p53 (D3) and of 
mESCs with genetically deleted p53 (p53
-/-
) and tested for quality. Yield: numbers of bases for 
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each sample; PF: clusters passing illumina chastity filter, (readings with no overlapping or unclear 
signal) Reads: number of fragment that were read; %of >=Q30: percentage of fragments with  
misreadings smaller than 2
-30
; Mean Quality Score (PF): average score of the fragments with less 
than 2
-30 
misreadings.  
The sequencing resulted in more than sixty-seven million reads per sample each of 
which being 50 nucleotides long with a mean Phred quality score over 35 and a 
reading errors smaller than two to the minus thirty-five.  
 
Figure 3.18 | p53 controls gene expression in mESCs. The transcriptome of wild-type and 
p53-negative (p53
−/−
) mESCs cells was analysed by RNA sequencing. The graph was generated 
using the data analyzing software R. The expression of each gene was calculated in log10, and 
plotted. Genes with a fold change≥2 in their expressions are shown as red circles.  
The reads were mapped against the mouse genome M37 database and gene expression 
was determined by counting for each gene the number of reads that overlapped with 
the annotation in the Ensembl release 67 database. Differences in gene expression 
were determined with the R package DESeq.  
As shown in figure 3.20, the majority of the expressed genes overlapped between 
p53-positive and p53-negative mESCs, indicating that expression of most of the genes 
is independent of p53 (Figure 3.20). However, some genes were differently expressed 
and either upregulated or downregulated in wild-type mESCs (Figure 3.20, Table 3.2). 
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Most interestingly, among the genes that are induced by p53 in stem cells are several 
proto-oncogenes (Table 3.2).  
Gene 
 p53
+/+
/p53
-/-
 (mESCs) 
 ↑ ↓ → 
c-fos  ×   
c-myc  ×   
c-jun  ×   
mdm2  ×   
akt1  ×   
mdmx    × 
igf2  ×   
lef1   ×  
Table 3.2 | Examples of genes regulated by p53 in mESCs. RNA was prepared from wild-type 
and p53
-/-
 mESCs, transcribed into cDNA and sequenced. Abundance of transcripts of the 
individual genes was determined and normalized to an internal control. ↑, gene expression was 
induced by p53; ↓, gene expression was repressed by p53; →, gene expression was not regulated 
by p53. 
To consolidate the result from RNA sequencing, I performed qRT-PCR for some of 
the genes. Therefore, I prepared RNA from mESCs and from their p53-negative 
counterpart, transcribed this RNA into cDNAs and performed SYBR-GREEN based 
quantitative real time PCR. In accordance with data from differentiated cells (Riley et 
al., 2008) and from RNA sequencing, expression of mdm2 and p21 was higher in 
p53-positive mESCs (Figure 3.19A). Moreover, and in agreement with the RNA 
sequencing data (Table 3.2), expression of akt1, c-myc, c-jun and igf2 was also 
significantly higher in p53-positive mESCs than in p53-negative mESCs (Figure 
3.19B). These increases were not due to an overall increase in gene expression as e.g. 
expression of lef1 was reduced in wild-type ESCs compared to p53
-/-
 mESCs (Figure 
3.19B).  
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Figure 3.19 | Several proto-oncogenes are induced by p53 in stem cells. RNA was prepared 
from p53
+/+
 mESCs and from p53 their negative counterparts (p53
-/-
 mESCs) and transcribed into 
cDNA. The cDNA was diluted in nuclease free water and 4μl of this diluted cDNA solution was 
used to perform SYBR-GREEN-based quantitative real time PCR using gene-specific primers. For 
internal control, abundance of the RNA of the housekeeping gene RibPO was determined. The 
relative abundance of specific cDNAs was calculated with the ΔΔCT method. Blotted are the mean 
values and error bars of two independent experiments. Relative abundance of the specific RNA in 
wild-type mESCs was set to 1. A. Classic p53 target genes. B. targets of wild-type p53 specifically 
in mESCs.  
To see whether the induction of these stem cell-specific target genes of p53 is also 
translated into proteins, I performed western blotting. I harvested p53-positive and 
p53-negative mESCs, lysed the cells in NP-40 lysis buffer and separated the extracts 
by SDS-PAGE. After transfer I hybridised the membrane with an antibody directed 
against c-Jun and with antibodies directed against p53, and -Actin for control.  
 
Figure 3.20 | c-Jun is induced by p53 in mESCs. Wild-type mESCs and mESCs with a genetic 
deletion of p53 (p53
-/-
) were lysed. 30μg of the lysate were separated by SDS PAGE and 
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transferred onto a PVDF membrane. Abundance of c-Jun and p53 was monitored by hybridization 
with an anti-c-Jun (H-79, diluted 1:2,000) and an anti-p53 (1C12, diluted 1:10,000) antibody 
respectively as described in the legend to figure 3.1. Abundance of β-Actin (I-19, diluted 1:1,000) 
was determined for loading control. 
As shown in figure 3.20, mESCs with wild-type p53 possessed more c-Jun protein 
than p53
-/-
 mESCs (Figure 3.20).  
To further support that p53 regulates proto-oncogenes such as c-jun and c-myc in 
mESCs, I treated the cells with Nutlin, a chemical activator of Mdm2 that fits into the 
p53-binding pocket on the Mdm2 protein and thus prevents its interaction with p53, 
resulting in increased p53 levels and activity (Vassilev et al., 2004). If these 
proto-oncogenes are indeed induced by p53 in mESCs, expression of these genes 
should be elevated after Nutlin treatment in p53-positive but not in p53-negative 
mESCs. To investigate this rationale, I plated p53-positive and p53-negative stem 
cells. For control, I employed mESCs that had been differentiated by incubation with 
retinoic acid for seven days since it has been shown that Nutlin stimulates p53 activity 
in differentiated cells (Vassilev et al., 2004). Half of the cells were treated with Nutlin 
for 24 hours. I then monitored abundance of c-Jun by Western blotting and abundance 
of c-myc by qRT-PCR. To monitor the activity of Nutlin, I also measured the 
abundance of MDM2 and p21 since these classical targets of p53 have been shown to 
be induced after Nutlin treatment (Giono and Manfredi, 2007)  
As shown in figure 3.21, the presence of Nutlin not only resulted in a p53-dependent 
induction of the classical p53 targets MDM2 and p21 but also in the induction of 
c-Jun and c-myc in mESCs (Figure 3.21). This induction only occurred in 
p53-positive mESCs, demonstrating the p53-dependence. Surprisingly, Nutlin also 
induced c-Jun in differentiated cells. However, while the induction of c-Jun in stem 
cells was p53-dependent, the induction of c-Jun by Nutlin also occurred in 
p53-negative cells (Figure 3.21). In contrast, Nutlin did not induce c-myc in 
differentiated cells. As expected, p53 and its target MDM2 were clearly induced after 
Nutlin treatment in mESCs and mESCs differentiated cells, proving the authenticity 
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of this experiment (Figure 3.21).  
 
Figure 3.21 | c-Jun is induced by Nutlin. mESCs, their p53-negative counterpart (p53
-/-
) and 
mESCs and p53
-/-
 cells that had been differentiated with retinoic acid for seven days (mESCs diff., 
p53
-/-
 diff.) were treated with 5 µM Nutlin for 24 hours. A. The cells were lysed and 30μg of lysate 
were separated by SDS PAGE and transferred onto a PVDF membrane. Abundance of c-Jun (H79, 
diluted 1:2,000), MDM2 (4B2, diluted 1:1,000) and p53 (1C12, diluted 1:10,000) was determined 
by western blotting as described in the legend to figure 3.1. Hybridization with an antibody 
directed against -Actin was performed for loading control. B. RNA was prepared and processed 
as described in the legend to figure 3.19. The graph shows mean values and error bars of two 
independent experiments. Relative abundance of the specific RNA in mock-treated cells was set to 
1. 
After having proven that c-Jun and c-myc are induced by the p53 activator Nutlin in 
mESCs, I reasoned that if p53 indeed induces c-Jun in stem cells, then this induction 
should be altered when the endogenous regulators of p53 activity, MDM2 and 
MDMX are downregulated. To follow on this rationale, I transfected mESCs with 
A 
B 
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siRNAs targeted against p53, MDM2 and MDMX. Seventy-two hours after siRNA 
transfection I harvested the cells and prepared two aliquots of the cells. One of the 
aliquots, I lysed and monitored abundance of c-Jun by western blotting. To control for 
the downregulation, I also monitored p53, MDM2 and MDMX levels by western 
blotting. I furthermore monitored abundance of the classical p53 targets Bax and 
Puma by western blotting which are involved in the anti-proliferative activity of p53. 
From the second aliquot, I prepared RNA and monitored abundance of the p53 target 
p21 by qRT-PCR.  
In support of the previous data, downregulation of p53, or of MDM2 or MDMX, 
which are endogenous inhibitors of p53, increased the abundance of c-Jun while 
downregulation of p53, reduced its abundance (Figure 3.22A). In contrast, abundance 
of Bax or Puma was not changed, indicating that these genes are not controlled by p53 
in mESCs under normal growth conditions (Figure 3.22A). Abundance of the p53 
target p21 was reduced after downregulation of p53 but was not grossly altered after 
downregulation of MDM2 or MDMX (Figure 3.22B).  
Since p53 obviously stimulates the expression of some proto-oncogenes in mESC, I 
wondered whether p53 could be found at the promoter region of these genes. I first 
checked whether there is a classical p53 binding motif in the promoter and enhancer 
elements of proto-oncogenes that are induced by p53 in stem cells. However, there 
was none of the known p53 response elements in any of these genes.  
Most interestingly, mutant p53 also stimulates expression of some proto-oncogenes 
and among the proto-oncogenes that are induced by mutant p53 is c-myc and c-jun, 
which are also induced by p53 in mESCs (Freed-Pastor and Prives, 2012; Huang et al., 
2013; Walerych et al., 2012). I reasoned that if wild-type p53 in mESCs behaves 
similar to mutant p53 in human tumour cells, and mutant p53 binds to the c-myc 
promoter, then wild-type p53 in stem cells might also bind to this region and decided 
to perform chromatin-immunoprecipitations (ChIP). Since it was already described 
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that mutant human p53 binds to the c-myc promoter (Huang et al., 2013), I selected 
primers for ChIP for the murine c-myc promoter that corresponded to that region. For 
akt1 or c-jun, I could not find published promoter sequences to which mutant p53 
binds. However, it was reported that mutant p53 preferentially and autonomously 
binds to G/C-rich DNA elements around transcription start sites of several genes 
(Quante et al., 2012). I therefore checked whether the transcription start sites of akt1 
and c-jun contain G/C-rich elements. As this was the case, I designed primers that 
would allow amplifying this region.  
 
Figure 3.22 | Downregulation of MDM2 or MDMX increases abundance of c-Jun in mESCs. 
mESCs were transfected with a siRNA targeted against p53 (40μM, f.c.), MDMX (40μM, f.c.), 
MDM2 (40μM, f.c.) or with a control siRNA (40μM, f.c.). After harvesting, the cells were 
separated into two parts. A. One of the samples was lysed with NP-40 lysis buffer and 30 µg of 
cellular protein were separated by SDS PAGE and transferred onto a PVDF membrane. The 
abundance of c-Jun (H-79, diluted 1:2,000), Puma (diluted 1:5,000), Bax (diluted 1:5,000), p53 
(1C12, diluted 1:10,000), MDM2 (4B2, diluted 1:1,000) and MDMX (diluted diluted 1:3,000) was 
determined as described in the legend to Figure 3.1. B. From the second part, RNA was prepared 
and processed as described in the legend to figure 3.19. The graph shows mean values and error 
bars of two independent experiments. Relative abundance of p21 RNA in control 
siRNA-transfected cells was set to 100%. 
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I then plated mESCs, their p53 negative derivatives (p53
-/-
) and mESCs and p53
-/-
 
mESCs that had been differentiated by incubation with retinoic acid for seven days. I 
fixed the protein/DNA complexes by incubation with formaldehyde, lysed the cells, 
isolated the nuclei, fragmented the DNA by sonication and precipitated p53 with an 
polyclonal antibody directed against the tumor suppressor protein. After 
immunoprecipitating p53, I removed the cross-links between protein and DNA, 
digested all proteins by incubation with proteinse K, eluted the DNA and performed 
RT-PCR with the selected primers. To control for the ChIP procedure, I included a 
PCR reaction with primers corresponding to the p53 binding site in the MDM2 gene, a 
classical target of p53 that was also regulated by p53 in mESCs (Table 3.2, Figures 
3.19, 3.21, 3.22) 
As shown in figure 3.23, the promoter region of c-jun, akt1 and c-myc indeed 
co-precipitated with the p53 protein when an immunoprecipitation was performed 
with an anti-p53 antibody. The intensity of the signal for the c-jun, akt-1 and c-myc 
promoters was, moreover, comparable to the intensity of the signal for the mdm2 
promoter, a classical and well-known p53 target (Figure 3.23A) (Freedman et al., 
1997), showing that p53 is indeed found around the transcriptional start site of these 
genes. Importantly, I could only precipitate akt1, c-myc and c-jun DNA with an 
anti-p53 antibody in p53-positive stem cells (Figure 3.23A), but not in p53-negative 
stem cells. I could also not precipitate these DNAs in differentiated cells with a p53 
antibody (Figure 3.23B), indicating that the transcription of akt1 or c-myc by 
wild-type p53 is specific for stem cells.  
p53 is best known for its anti-proliferative activity in response to DNA damage (Lane, 
1993). After having demonstrated that p53 indeed induces a novel set of genes in 
mESCs, I wondered whether these genes are also induced by p53 in response to DNA 
damage. To see whether this induction of proto-oncogene in response to DNA damage 
is p53-dependent, I also employed p53
-/-
 mESCs. To induce DNA damage, I applied 
the topoisomerase inhibitor Etoposide (Eto) that induces DNA strand breaks 
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(Pommier et al., 2010). I then monitored abundance of p53 and its target genes by 
Western blotting and qRT-PCR. 
 
Figure 3.23 | p53 is associated with the promoter regions of c-myc, c-jun and akt1 in stem 
cells. A. Wild type mESCs (p53
+/+
 mESCs) and their p53-deficient counterpart (p53
-/- 
mESs) were 
fixed with 1% formaldehyde (f.c.) for 10 minutes at room temperature. Fixation was stopped 
byaddition of glycine (0.125M f.c.) and incubation for 5 min at RT. The cells were lysed in 5mM 
HEPES pH 8, 85mM KCL, 0.5% NP40, 1mM PMSF, 1µg/ml aproptinin, 1µg leupeptin, the nuclei 
were pelleted and suspended in nuclei-lysis buffer (50mM Tris pH 8.1, 10mM EDTA pH 8.0, 1% 
SDS, 1mM PMSF, 1µg/ml aproptinin, 1µg/ml leupeptin). After incubation for 10 min on ice, the 
lysate was sonicated to achieve an average length of the chromatin of about 400bp. The lysate was 
divided into three parts. 10% were conserved for input, 45% were incubated with the anti-p53 
antibody CM5 and 45% were incubated with IgG O/N at 4°C. Protein A agarose was added and 
the samples were incubated for a further hour. After washing, the cross-links were removed, the 
proteins digested with proteinase K and the DNA was purified by phenol extraction. The purified 
DNA was diluted with nuclease free water and 2µl of the diluted DNA was used to perform PCR. 
Precipitation with IgG and total cell lysate (Input) were used for positive and negative control. The 
PCR products were separated by agarose gel electrophoresis and photographed B. Differentiated 
mESCs (p53
+/+
 diff.) and p53-deficient differentiated cells were processed as described in the 
legend to part A. 
As shown previously for the treatment with ionizing irradiation (Solozobova et al., 
2009), induction of DNA damage resulted in a strong induction of the p53 protein and 
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a strong increase in the expression of the classical p53 target genes mdm2 and p21 
(Figure 3.24). This result shows that p53 in mESCs was activated by the etoposide 
treatment. When I investigated the expression of c-jun and lef1, which I have found to 
be induced and downregulated by p53 in mESCs, respectively (Figure Table 3.2), I 
observed that c-Jun was induced and that lef1 was downregulated after treating 
mESCs with etoposide. However, c-Jun was also induced and lef1 also downregulated 
in p53-negative cells (Figure 3.24). This result makes it questionable whether p53 
indeed contributes to the DNA-damage-dependent regulation of c-jun and lef-1. c-myc, 
which was normally induced by p53 in stem cells, was even reduced in response to 
etoposide treatment. Since this reduction also occurred in p53-negative mESCs, this 
reduction in c-myc RNA abundance was most likely p53-independent (Figure 3.24). 
 
Figure 3.24 | Involvement of p53 in the regulation of proto-oncogenes in response to DNA 
damage. mESCs and their p53-negative counterpart (p53-/-) were treated with 50µM etoposide or 
with ethanol for control. 4.5 hours after treatment, cells were harvested. The cells were divided 
into two aliquots. A. One of the aliquots of the cells was lysed, and 30µg of the lysate were 
separated by SDS-PAGE and transferred onto a PVDF membrane. Abundance of p53 and c-Jun 
was monitored by hybridization of the membranes with an anti-p53 antibody (1C12, diluted 
1:10,000) and an anti-c-Jun antibody (H79, diluted 1:2,000) as described in the legend to figure 
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3.1. B. From the second aliquot, RNA was prepared and processed as described in the legend to 
figure 3.19. The graph shows mean values and error bars of two to three independent experiments. 
Relative abundance of the specific RNA in mock-treated cells was set to 1. 
Overall, these results demonstrate that p53 is active in mESCs and capable of 
influencing the transcriptional program. Most remarkably, p53 controls expression of 
a different set of genes in mESCs than in differentiated cells. Curiously, several of the 
genes that are controlled by wild-type p53 in mESCs are controlled by mutant p53 in 
tumour cells. 
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4 DISCUSSIONS 
4.1 The p53 protein is primarily localized in the nuclear 
compartment in mESCs. 
In order to explain how stem cells maintain a high proliferation rate regardless of a 
high amount of p53, I firstly monitored the localization of p53 in mESCs. Since p53 is 
primarily a transcription factor, the import and retention of p53 in the nucleus is 
important for its function. Therefore, an abnormal subcellular localization, i.e. in the 
cytoplasm, could be a reason for its weak effect on cell growth. Indeed previous 
reports claimed that p53 is localized in the cytoplasm after detecting p53 by 
immunofluorescence staining and cell fractionation with the anti-p53 antibodies 
Pab421 and Pab246 (Aladjem et al., 1998; Solozobova et al., 2009; Han et al., 2008). 
In consistency with these reports, I also got a signal in the cytoplasm when I was 
using the anti-p53 antibody Pab421. However, with this antibody, I also observed a 
signal in the cytoplasm of p53 negative mESCs. This result indicates that the signal in 
the cytoplasm was due to the poor specificity of the anti-p53 antibodies Pab421. 
Further exploration of p53’s localization in mESCs by using the anti-p53 antibodies 
1C12 and CM5 showed that the majority of p53 is localized in the nuclear 
compartment. Since these antibodies gave no signals in p53-negative cells, they are 
indeed specific for p53. This result was further confirmed by western blotting after 
cell fractionation. In consistency with the immunofluorescence staining, the signal 
around fifty-three kDa that was detected by the antibodies Pab246 and Pab421 in the 
cytoplasm was unspecific. Only the antibodies 1C12 and CM5 showed a good 
specificity and here, the p53 signal was primarily in the nuclear compartment in 
mESCs. However, there was also some p53 in the cytoplasm. This cytoplasmic 
localization of p53 is, however, not specific for stem cells and is also observed in 
differentiated cells, where cytoplasmic p53 contributes to the induction of apoptosis 
Moll et al., 2005). To further confirm the nuclear localization of p53, I have treated a 
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part of the mESCs with the drug leptomycin B (LMB). LMB inhibits CRM1 
(chromosome region maintenance 1)-dependent export of proteins from the nucleus 
into the cytoplasm (Jang et al., 2003; Kudo et al., 1999; Wolff et al., 1997). CRM1 is a 
member of the importin-beta superfamily of nuclear transport receptors. These 
receptors recognize proteins that contain a leucine-rich nuclear export sequence (NES) 
as it is present in p53 Fornerod et al., 1997; Zhang and Xiong, 2001; Ossareh-Nazari 
et al., 1997). CRM1 has been shown to be required for the export of p53 from the 
nucleus into the cytoplasm in differentiated cells (Freedman and Levine, 1998; 
Stommel et al., 1999). Accordingly, p53 accumulated in the nucleus when tumor cells 
were treated with LMB, where p53 is primarily localized in nucleus (Hietanen et al., 
2000). Therefore, p53 should not accumulate in the nucleus after LMB treatment if 
p53 would be purely localized in the cytoplasm. After LMB treatment, I observed that 
p53 indeed accumulated in the nucleus, proving that p53 is indeed localized in the 
nucleus in mESCs. However, I also observed that p53 accumulated in the cytoplasm 
after LMB treatment. This result suggests that proteins are involved in the degradation 
of cytoplasmic p53 that need to be exported from the nucleus. Alternatively, LMB 
could have additional activities, apart from preventing CRM1-mediated nuclear 
export.  
 
4.2 The anti-proliferative activity of p53 is compromised in 
mESCs. 
p53 is a tumor suppressor protein that suppresses cell proliferation primarily by  
induction of p21/WAF1 (el-Deiry et al., 1993; Tang et al., 1998), an inhibitor of 
cyclin-dependent kinase 2 that regulates the cell cycle at the G1/S phase (Xiong et al., 
1993; Harper et al., 1993). In addition, p53 represses cell proliferation by inducing 
Gadd45 and 14-3-3-σ, which inhibit CDC2, the cyclin-dependent kinase that is 
required to enter mitosis (Hermeking et al., 1997; Wang et al., 1999).  
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Since p53 is obviously localized in the nucleus in mESCs, and also since its 
abundance is higher in mESCs than in somatic cells, I wondered how stem cells can 
proliferate fast regardless of the high amount of p53 which normally has an 
anti-proliferative effect when it is localized in the nucleus. When I investigated the 
proliferation of p53-positive and p53-negative mESCs, I found that the proliferation 
rate of p53 positive mESCs is similar to that of p53 negative mESCs. Only on day3 
and day4, I observed a minor difference, which was probably due to a reduction in the 
stemness of the mESCs since they were cultivated four days without sub-culturing 
them. Yet, mESCs is a sensitive cell type and requires passaging at least every two 
days to maintain their stem cell properties. This result explains how mESCs can 
proliferate despite having high amounts of p53, namely by switching off p53’s 
anti-proliferative activity.  
 
4.3 p53 is differently modified in stem cells and 
differentiated cells 
Since p53 is nuclear in stem cells as it is in differentiated cells, the localization of p53 
cannot be the reason for its inactivation in mESCs. However, p53’s activity is largely 
controlled by posttranslational modifications (PTMs) (Appella and Anderson, 2001; 
Bode and Dong, 2004; Brooks and Gu, 2003; Oren, 1999; Vogelstein et al., 2000; 
Vousden and Lu, 2002). I therefore wondered whether distinct PTM in mESCs and 
differentiated cells could account for p53’s compromised activity in stem cells. p53 is 
regulated by PTMs in two ways: i) PTMs control p53 stability and ii) PTMs alter the 
activity of preexisting p53 molecules (Boehme and Blattner, 2009). For the regulation 
of p53 stability, p53 is primarily modified by ubiquitin-ligases. The most well-studied 
ubiquitin ligase is MDM2, which induces both monoubiquitination and 
polyubiquitination of p53 Li et al., 2003). Polyubiquitinated p53 is recognized by 26S 
proteasomes where it is subsequently degraded (Love et al., 2013). Apart from 
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ubiquitin, p53’s stability is also regulated by other small ubiquitin-like proteins, such 
as SUMO (small ubiquitin-like modifier) (Rodriguez et al., 1999) and NEDD8 
(Xirodimas et al., 2004). The activity of p53 is furthermore regulated by 
phosphorylation, acetylation and methylation (Chehab et al., 2000; Sakaguchi et al., 
2000; Shieh et al., 2000). Yet it should be noted that several of these modifications 
may have a clear function under experimental condition but may not modify the p53 
protein under physiologic conditions.  
To see whether p53 is differently modified in mESCs and differentiated cells, I 
employed commercially available antibodies against acetylated p53 at lysine 379, or 
phosphorylated at serine 18, serine 9 or at serine 389 (corresponding to human lysine 
382, serine 6, serine 15 and serine 392 respectively). All these modifications enhance 
p53’s transcriptional activity. Phosphorylation of serine-15 decreases its affinity for its 
negative regulator MDM2 and promotes its transcriptional activity by recruiting the 
transcriptional coactivator p300 (Lambert et al., 1998). Phosphorylation of serine 392 
is induced in response to UV exposure (Keller and Lu, 2002), and increases the 
stability of p53’s tetramers and inhibits the exportation of p53 into the cytoplasm 
(Kim et al., 2004; Sakaguchi et al., 1997). Acetylation of p53 at lysine 379, on the 
other hand, is one of the most important acetylation sites. This acetylation is 
stimulated by phosphorylation of p53 at the N terminal domain since this 
phosphorylation recruits p300/CBP that subsequently acetylates lysing 379 (Jenkins et 
al., 2009; Polley et al., 2008). None of the employed antibodies recognized p53 from 
undamaged cells, neither from stem cells nor from differentiated cells, apart from the 
antibody that was directed against serine 392, yet the signal was very weak. After 
DNA damage, p53 was strongly induced and highly modified at serine 15, serine 392 
and at lysine 379. Serine 6 was only phosphorylated in differentiated cells and the 
signal was very weak.  
Since none of the modifications occurs in undamaged stem cells, these modifications 
cannot explain why the anti-proliferative activity of p53 is compromised in mESCs. 
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Most interestingly, V. Solozobova in our lab has already found that some p53 with a 
neutral pI (between 6.4 to 8.2) was exclusively present in mESCs and not in 
differentiated cells. I wondered whether this fraction of p53 differed in 
phosphorylation and acetylation from p53 of differentiated cells since these 
modifications could greatly influence the overall charge of the modified protein 
resulting in a change in the isoelectric point (Zhang et al., 2009; Zhu et al., 2005). 
Therefore, I treated the cell lysate of mESCs and of differentiated mESCs with 
λ-phosphatase to remove the phosphate groups of the proteins including p53, or I 
treated the cells with the inhibitors of histone acetyltransferases trichostatin A and 
nicotinamide (Bitterman et al., 2002; Gottlicher et al., 2001) to increase the 
acetylation level of the proteins including p53, After the treatment, I performed 
2-dimensional gel electrophoresis followed by Western blotting. I observed that 
treatment of the lysate of stem cells with λ-phosphatase shifted a fraction of p53 
beyond a pI of 8.6. In samples that had not been treated with the phosphatase, there 
was no p53 with a pI greater than 8.6 at least not to this extend. This result shows that 
p53 in stem cells is constitutively phosphorylated. For differentiated cells, I obtained a 
similar result. Here, the negative charge of p53 was also reduced after phosphatase 
treatment. However, no p53 with a pI beyond 8.6 was detected in these samples. In 
fact, p53 from differentiated cells that had been treated with phosphatase resembled 
untreated p53 from stem cells. In addition, the treatment of TSA/NA strongly 
increased the negative charge of p53 from stem cells resulting in the complete 
removal of the fraction of p53 with a neutral pI. In differentiated cells, there was also 
a tendency to increase the fraction of p53 with a very acidic pI between 4.6 and 5.2. 
The effect was, however, not as obvious as in stem cells. All these evidences indicate 
that the neutral pI of p53 is determined by phosphorylation and acetylation. However, 
it remains to be determined which amino acid/acids is/are differently modified with 
phosphorylation and acetylation in stem cells and differentiated cells.  
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4.4 MDMX controls p53’s activity in mESCs. 
Since a fraction of p53 with a neutral pI is exclusively present in mESCs, I wondered 
whether this may affect the association of p53 with other proteins. Sucrose gradient 
assays proved that the majority of p53 is always associated with other proteins either 
in mESCs or in differentiated cells. However, there was no clear difference in the 
elution of p53 from the sucrose gradient no matter whether it was derived from stem 
cells or from differentiated cells. I also monitored the elution profile of MDM2 and 
MDMX, two major negative regulators of p53. MDM2, functions as an E3 ubiquitin 
ligase, that regulates the abundance and activity of p53 (Haupt et al., 1997; Honda et 
al., 1997; Itahana et al., 2007; Kulikov et al., 2010). MDMX is a close homolog of 
MDM2. It controls p53 abundance and inactivates p53 in somatic and cancer cells 
(Finch et al., 2002; Jackson and Berberich, 2000; Shvarts et al., 1997; Shvarts et al., 
1996). However, only a minor fraction of MDM2 co-eluted with p53 from sucrose 
gradients, indicating that less than half of the p53 protein might be associated with 
MDM2. MDMX, in contrast, has a similar elution profile as p53, which is consistent 
with the reported ability of these two proteins to associate with each other (Shvarts et 
al., 1996). MDMX is moreover highly abundant in stem cells and present in negligible 
amounts in differentiated cells. It is therefore most likely that MDMX is associated 
with p53 and controls its activity in stem cells. Co-IP experiments and downregulation 
assays that have been performed in our research group by V. Solozobova and me 
confirmed that MDMX is associated with p53 and control p53’s anti-proliferative 
activity while downregulation of MDM2 had a minor effect for p53’s activity in 
mESCs (Yan et al., 2015). This result could explain why stem cells are able to 
proliferate so fast regardless of the high amount of p53. Nevertheless, although 
MDMX plays an important role for controlling p53’s activity in mESCs, recent 
studies in our lab and others indicate that MDMX may not be the only factor. TRIM25 
for instance, a member of the TRIM super family, inhibits p53’s transcriptional 
activity (Zhang et al., 2015). TRIM25 is also more abundant in stem cells than in 
differentiated cells (Ping Zhang, personal communication), indicating that it may also 
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contribute to the control of p53 activity in mESCs. This regulatory network of p53 in 
mESCs needs to be further investigated in the future.  
After I have observed that MDMX expression was decreased during differentiation, I 
wondered by which mechanism MDMX could be regulated. Alternative splicing is an 
efficient mechanism to modulate MDMX protein abundance (Boutz et al., under 
revision). Alternative splicing of MDMX decreases the inclusion of exon 7 of MDMX, 
and the absence of exon 7 results in a very unstable transcript known as MDMX-S. 
The MDMX-S isoform contains a premature termination codon and is targeted for 
non-sense mediated decay (Rallapalli et al., 1999). The consequence of this exon 7 
skipping results in overly active p53. In consequence, mice homozygous for the 
deletion of MDMX exon 7 die in utero, just like MDMX-null embryos, due to ectopic 
p53 activation (Bardot et al., 2014; Parant et al., 2001). I observed that the amount of 
the full lengths MDMX RNA (MDMX-FL) was decreased during differentiation while 
the amount of the shorter form of the MDMX RNA (MDMX-S) with skipped exon7 
was increased. Since rather the ratio between MDMX-S and MDMX-FL than the 
absolute abundance seems to be important for the fate of MDMX, we also measured 
the ratio between MDMX-FL and MDMX-S. Importantly, the ratio of MDMX-FL and 
MDMX-S parallels the decrease in MDMX protein levels in mESCs when the cells 
have been exposed to the differentiation promoting agent retinoic acid. Thus, it is 
most likely that alternative splicing contributes to the downregulation of MDMX 
during differentiation.  
 
4.5 Splicing of p53 is altered during retinoic acid induced 
differentiation 
Since I had already found that the splicing of MDMX is altered during differentiation, 
I wondering whether the splicing of p53 would also be altered, particularly since a 
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different splicing pattern alters the activity of p53 (Bourdon et al., 2005). The isoform 
Δ40p53α, for instance, which is generated by alternative splicing of intron 2 and lacks 
the first 39 amino acids and thus the major transactivation domain 1 (TAD1), has a 
dominant-negative effect over full length p53. It inhibits the transcriptional activity of 
full length p53, and impairs p53-mediated growth suppression (Courtois et al., 2002);. 
It is thus possible that alternative splicing of p53 could contribute to its partial 
inactivation in mESCs..  
In order to investigate whether p53 is spliced differently in stem cells and 
differentiated cells, I induced differentiation of stem cells by retinoic acid and 
monitored abundance of p53 by using an antibody against alternatively spliced 
isoforms as well as an antibody that recognizes full lengths p53. In consistency with 
previous work (Sabapathy et al., 1997; Solozobova and Blattner, 2010), abundance of 
full length p53 decreased during retinoic acid induced differentiation, while a signal 
around 48kDa was increased, which most likely represents theΔ40p53 and the 
Δ40p53AS isoforms. Most interestingly, two other signals were increased strongly 
after retinoic acid induced differentiation, one at around 40kDa and the other one at 
around 18kDa. The signal at around 18kDa represents most likely the recently 
described p53 isoform p53Ψ (Senturk et al., 2014). An isoform of p53 with a 
molecular weight around 40 kDa has not been described as yet and may represent a 
novel and stem cell specific isoform.  
 
4.6 Wild type p53 in mESCs controls the transcriptome in a 
manner similar to mutant p53 in differentiated cells. 
Since the abundance of p53 is higher in stem cells than in differentiated cells 
(Sabapathy et al., 1997; Solozobova and Blattner, 2010), yet its anti-proliferative 
activity was compromised, I was particularly interested in finding out whether p53 
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may have another function in stem cells. By performing RNA sequencing, I found that 
several genes are expressed differently in mESCs and differentiated cells.  
Most interestingly, some of the genes that are expressed at a higher level in 
p53-positive stem cells including akt1, c-myc, c-jun and igf2 were reported to be 
transactivated by mutant p53 in cancer cells (Freed-Pastor and Prives, 2012; Walerych 
et al., 2012). This implies that wild-type p53 in stem cells may have acquired 
properties of tumor-derived mutant p53. Interestingly, p53 from stem cells associated 
with the same region of the c-myc promoter that is occupied by mutant p53 in 
differentiated cells (Huang et al., 2013). Further, p53 was associated with GC-rich 
regions around the transcriptional start site of c-jun and akt1 in mESCs, a property 
that has been described for mutant p53 in cancer cells (Quante et al., 2012).  
As mESCs express wild type p53, it is paradox that p53 acts like mutant p53 in 
mESCs. Eventually, p53’s conformation is altered by chaperones such as the heat 
shock proteins, which have been reported to influence the affinity of p53 to the 
promoter region of its targets. Inhibition of heat shock protein 90 by geldanamysin, 
for instance, diminishes the binding of p53 to the p21 promoter sequence in 
differentiated cells (Walerych et al., 2004).  
Which mechanisms are responsible for the altered function of p53 in mESCs merits 
future investigations. 
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6. ABBREVIATIONS 
Abbreviation Full name 
A Ampere 
Ac Acetylation 
AFP Alphafeto protein 
AP Alkaline phosphate 
APS Ammonium persulfate 
BSA Bovine serum albumin 
cDNA Complementary DNA 
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate 
hydrate 
CT Cycle threshold 
C-terminus Carboxyl-terminus 
ºC Degrees Celcius 
d Day 
DBD DNA binding domain 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimthysulfoxide 
DNA Deoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTPs Deoxyribonucleotides 
ECL Enhanced chemiluminescence 
EDTA Ethylenediamine tetraacetic acid 
EMT Epithelial-mesenchymal-transition 
ESCs Embryonic stem cells 
et al. Et alii, and others 
Eto Etoposide 
f.c. Final concentration 
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FDA Food and Drug Administration 
GOF gain-of-function 
h Hour 
HAT histone acetyltransferases 
HDAC1 histone deacetylase 1 
HEPES 2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethanesulfonic acid 
HRP Horseradish peroxidase 
i.e. id ist, that is 
IEF Isoelectric focusing 
iPSCs Induced pluripotent stem cells 
kDa kilo Dalton 
KO knockout 
L Liter 
LIF Leukemia inhibitory factor 
LMB Leptomysin B 
M Molar 
m Milli 
MDM2 mouse double minute 2 homolog 
MDMX mouse double minute 4 homolog 
Me Methylation 
MEFs Mouse embryonic fibroblast 
mESCs Mouse embryonic stem cells 
MET Mesenchymal-epithelial-transition 
min Minute 
μl Microliter 
ml Milliliter 
MOMP Mitochondrial outer membrane permeabilization 
mRNA Messenger RNA 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
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n Nano 
NA Nicotinamide 
NEAA Non-essential amino acid 
NEM N-Ethylmaleimide 
NES Nuclear export signal 
NL Non-linear 
NLS Nuclear localization signal 
NP-40 Nonodet-P40 
N-terminus Amino-terminus 
o.n. overnight 
P phosphorylation 
PAGE Polyacrylamide gel electrophoresis 
PBS(T) Phosphate buffered saline (Tween20) 
PCR Polymerase chain reaction 
pH Potential of hydrogen 
pI Isoelectric point 
PMSF Phenylmthanesulfonyl fluoride 
PRD Proline rich domain 
PTMs Posttranslational modifications 
PVDF Polyvinylidene difluoride 
qRT-PCR Quantitative Real-time PCR 
RE Responsive element 
REG Regulatory domain 
RNA Ribonucleic acid 
RNase Ribonuclease 
rpm  Revolutions per minute 
RT-PCR Reverse transcription PCR 
sec Second 
SDS Sodium Dodecyl Sulfonate 
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SUMO Small ubiquitin-like modifier 
TAD Transactivation domain 
TAE Tris Acetate-EDTA buffer 
TAF9 TBP associated factor 9 
TBP TATA binding protein 
TBS(T) Tris buffered saline (Tween20) 
TCA Trichloroacetic acid 
TSA Trichostatin A 
TEMED N,N,N’,N’-Tetramethylethylenediamine 
TET Tetramerization domain 
TM Tris magnesium sulfate 
Tris Tris(hydroxymethyl)aminometane 
UV Ultraviolet 
V Volt 
W Walt 
w/o without 
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